СПОСОБ ПРОИЗВОДСТВА ИГРИСТОГО ВИНА В НЕПРЕРЫВНОМ ПОТОКЕ

Изобретение может быть использовано в винодельческой промышленности, а именно в производстве игристых вин непрерывным способом. Способ производства игристого вина в непрерывном потоке предусматривает купажирование виноматериалов, получение водной суспензии природного дисперсного минерала и дрожжевой разводки, введение в купаж водной суспензии природного дисперсного минерала в резервуар с размещенным в нем наполнителем в процессе подачи в него купажа и дрожжевой разводки. Затем осветление, фильтрацию и биологическое обескислороживание купажа проводят в этом резервуаре одновременно путем перемешивания купажа с дрожжевой разводкой и дисперсным минералом и пропускания потока смеси через наполнитель в виде стеклянных шариков с удельной площадью поверхности 10,8-13,7 м2/дал/час. Водную суспензию природного дисперсного минерала вводят в резервуар в виде разрозненных или предварительно смешанных с дрожжевой разводкой доз. Купаж подвергают пастеризации, шампанизации, биогенерации, фильтрации вина ...

СПОСОБ ПРОИЗВОДСТВА ШАМПАНСКОГО

Обработанный по известной технологии шампанский виноматериал непрерывно подают в ферментер, внутри которого размещен адсорбент, представляющий собой вертикальные продольно-секционирующие поверхности, при перемешивании. Здесь в присутствии флуктуирующих и иммобилизованных на поверхности адсорбента дрожжей, соотношение которых соответственно составляет 70-90% и 10-30% от их общего количества, проводят в равномерном потоке вдоль вертикальных поверхностей биологическое обескислороживание, после чего при перемешивании отводят виноматериал. Приготавливают бродильную смесь путем купажирования его с ликером, вводят в нее дрожжевую разводку и направляют на шампанизацию. Для чего бродильную смесь непрерывно подают при перемешивании в бродильный аппарат с размещенным в нем адсорбентом в виде вертикальных продольно-секционирующих поверхностей, на которых иммобилизируют дрожжевые клетки. Сбраживание ведут в равномерном потоке вдоль вертикальных поверхностей в присутствии флуктуирующих и иммобилизированных ...

СПОСОБ ПРОИЗВОДСТВА ШАМПАНСКИХ И ИГРИСТЫХ ВИН

Изобретение может быть использовано в винодельческой промышленности, в частности при производстве вин, пересыщенных диоксидом углерода. Известным путем из красных сортовых и белых виноматериалов приготавливают ассамбляжи, которые выдерживают в течение от 1 до 12 месяцев, из выдержанных ассамбляжей из белых виноматериалов отбирают часть и подвергают купажированию, затем подвергают ассамбляжи и купаж раздельной шампанизации непрерывным или периодическим методом. Шампанизированный ассамбляж из красного сортового виноматериала разделяют на две части, одну из которых направляют на фильтрацию и розлив. Шампанизированный ассамбляж из белых виноматериалов разделяют на четыре части, одну часть направляют на фильтрацию и розлив, вторую смешивают с другой частью шампанизированного ассамбляжа из красных сортовых виноматериалов в соотношениях, обеспечивающих производство красных и розовых игристых вин, подвергают фильтрации и розливу. Штампанизированный купаж также разделяют на три части, одну из них ...

Способ производства игристого вина

Изобретение относится к винодельческой промышленности. Способ производства игристого вина включает получение ассамбляжей из виноматериалов, их выдержку, приготовление купажа из виноматериалов, вторичное брожение и фильтрацию виноматериалов с получением сброженного вина, а также приготовление ликера, розлив в бутылки сброженного вина с добавлением в его состав ликера и сусального золота. Перед розливом сброженное вино смешивают с ликером с последующим охлаждением полученной базовой смеси до температуры от -2°С до +2°С (от минус 2°С до плюс 2°С), ее перемешиванием и фильтрацией. После этого отделяют часть полученной смеси, в которую вводят сусальное золото из расчета 0,0012-0,005 г на 1 л готового продукта. Розлив осуществляют при температуре не выше +2°С, при этом указанную часть отделенной смеси дозируют в бутылки из расчета 2-10% от объема бутылки, после чего бутылки доливают базовой смесью до полного заполнения. Изобретение позволяет увеличить производительность вина и повысить его органолептические ...

УСТАНОВКА ДЛЯ ПРИГОТОВЛЕНИЯ ТИРАЖНОЙ СМЕСИ В ПРОИЗВОДСТВЕ ИГРИСТЫХ ВИН

Установка для приготовления тиражной смеси в производстве вин, в том числе игристых, включающая установленные и сообщенные циркуляционной линией в технологической последовательности реактор, снабженный перемешивающими устройствами, паровой рубашкой и устройством для ввода пара снизу, регулятором температуры, дозаторы тиражного ликера и чистой культуры дрожжей, гомогенизатор, центробежный насос.

ШТАММ МОЛОЧНОКИСЛЫХ БАКТЕРИЙ LEUCONOSTOC OENOS L-04 - ДЛЯ БИОЛОГИЧЕСКОГО КИСЛОТОПОНИЖЕНИЯ КРАСНЫХ СТОЛОВЫХ ВИНОМАТЕРИАЛОВ

Штамм молочнокислых бактерий Leuconostoc L-04 - для биологического кислотопонижения красных столовых виноматериалов, депонированный как Leuconostoc oenos IMB B-7225.

СПОСОБ ПРОИЗВОДСТВА ИГРИСТОГО ВИНА

Использование: в винодельческой промышленности, например, при производстве игристых вин. Сущность изобретения: в шампанские бутылки разлили бродильную смесь купажа шампанских виноматериалов, ликера и дрожжевой разводки. После этого бутылку укупорили экспедиционной пробкой с укрепленным на нем конусом из полиэтилена и надели "мюзле". После завершения вторичного брожения осадок свели через отверстие конической насадки в полость пробки.

СПОСОБ ПРОИЗВОДСТВА МЕДОВОГО НАПИТКА

Использование: в пиво-безалкогольной промышленности. Сущность изобретения: приготавливают медовое сусло смешиванием купажа цветочных медов с прокипяченной с пряностями или без них водой с температурой 40oС из расчета получения сусла массовой долей сухих веществ 12-18%, непосредственно после чего сусло охлаждают до 20oС, вносят в него хлебопекарные дрожжи из расчета 5 г/гл сусла и сбраживают при температуре 18-22oС в течение 8-12 сут до обеспечения видимого экстракта 5-6%. Сусло охлаждают до 2-5oС, снимают с осадка, крепят спиртом-ректификатом до спиртуозности готового продукта 10-12 об. %, вносят подсластитель в количестве, эквивалентном 4-8% сахара, и дображивают в герметически закрытой емкости в течение 1-3 сут.

СПОСОБ ПРОИЗВОДСТВА ИГРИСТОГО ВИНА "ГУБЕРНАТОР"

Изобретение касается винодельческой промышленности. Ассамбляж шампанских виноматериалов обрабатывают и выдерживают в течение 3 - 5 месяцев, купажируют, выдерживают купаж в течение 3 - 5 месяцев, дезаэрируют, перед шампанизацией купаж подвергают тепловой обработке, приготавливают бродильную смесь, шампанизируют, выдерживают на холоде шампанизированное вино, дозируют экспедиционным ликером и разливают. Состав купажа устанавливают при следующем соотношении виноматериалов, дал на 1000 дал купажа: Алиготе 400 - 500, Пино 200 - 300, Рислинг 100 - 200. Предлагаемый способ позволяет повысить ароматику и игристые свойства вина.

СПОСОБ ПРОИЗВОДСТВА ШАМПАНСКОГО

Использование: в винодельческой промышленности. Сущность изобретения: из виноматериалов получают ассамбляжи, которые раздельно подвергают шампанизации, затем шампанизированные ассамблированные виноматериалы выдерживают, купажируют в зависимости от заданных стабильных качественных показателей готового продукта. Из шампанизированного вина готовят различные марки вин.

ИГРИСТОЕ ВИНО "ФЛАМИНГО"

Использование: изобретение относится к винодельческой промышленности, в частности к игристым винам. Сущность: вино "Фламинго" содержит белые шампанские и красные виноматериалы в следующем соотношении, об.%: белые шампанские виноматериалы 93 - 95, красные виноматериалы из винограда сорта Матраса и/или Пино-фран, и/или Каберне, и/или Саперави 5 - 7. 1 табл.

СПОСОБ ПРОИЗВОДСТВА ШАМПАНСКОГО

Способ производства шампанского, предусматривающий получение ассамбляжей из шампанских виноматериалов, выдержку их, купажирование и шампанизацию, отличающийся тем, что шампанизацию виноматериалов проводят раздельно после получения ассамбляжей, выдержке подвергают шампанизированные ассамблированные виноматериалы, а при купажировании используют выдержанные шампанизированные ассамблированные виноматериалы, количество которых подбирают в зависимости от стабильных заданных качественных показателей готового продукта.

СПОСОБ ПРОИЗВОДСТВА НАПИТКА ИГРИСТОГО "ПИНО-ДОН"

... 1. Способ производства напитка игристого с использованием виноградного сока сорта ПИНО, предусматривающий процессы купажирования, брожения, обработки при отрицательной температуре и розлива, отличающийся тем, что купажирование белого, розового или красного сока винограда сорта ПИНО осуществляют коньячным спиртом или коньяком. 2. Способ по п.1, отличающийся тем, что купажирование осуществляют до содержания спирта 8-9 об.% и содержания сахара не менее 110 г/дм3, брожение осуществляют до содержания спирта 10-12 об.% и содержания сахара 75-90 г/дм3, розлив проводят при давлении газа не менее 100 кПа.

СПОСОБ ПРОИЗВОДСТВА ГАЗИРОВАННОГО ВИНОГРАДНОГО ВИНА

... 1. Способ производства газированного вина, предусматривающий приготовление купажа с использованием сухих виноградных виноматериалов и ингредиента, повышающего сахаристость купажа, оклейку купажа, его фильтрацию, охлаждение, насыщение диоксидом углерода и розлив, отличающийся тем, что при приготовлении купажа используют ординарные обработанные виноматериалы, в качестве ингредиента, повышающего сахаристость купажа, используют концентрат виноградного сока с содержанием сахара 60 - 68 мас.дол.%, перед охлаждением купажа осуществляют его пастеризацию в течение двух мин при температуре 80 - 85oC с последующей вторичной фильтрацией, а насыщение купажа диоксидом углерода осуществляют при давлении 200 - 250 кПА. 2. Способ по п. 1, отличающийся тем, что в качестве ингредиента, повышающего сахаристость купажа, используют сахарный сироп с массовой концентрацией сахаров 50 - 60 г/100 см3. 3. Способ по п. 1, отличающийся тем, что для приготовления купажа розовых вин используют белые и красные виноматериалы ...

КОМПОЗИЦИЯ ИНГРЕДИЕНТОВ ШИПУЧЕГО ВИНОГРАДНОГО ВИНА "КАПРИЗ"

... 1. Композиция ингредиентов шипучего виноградного вина, содержащая столовое сухое вино, отличающаяся тем, что она дополнительно содержит сахар и смесь натуральных или идентичных натуральных душистых веществ при следующем соотношении ингредиентов в кг/1000 дал вина: Сахар - 450...650 Душистые вещества - 2...38 Столовое сухое вино - Остальное 2. Композиция по п. 1, отличающаяся тем, что она содержит душистое вещество с ароматом вишни в количестве 36...38 кг/1000 дал. 3. Композиция по п. 1, отличающаяся тем, что она содержит душистое вещество с ароматом грейпфрут/лимона в количестве 24...26 кг/1000 дал. 4. Композиция по п. 1, отличающаяся тем, что она содержит душистое вещество с ароматом апельсина в количестве 29...31 кг/1000 дал. 5. Композиция по п. 1, отличающаяся тем, что она содержит душистое вещество с ароматом персика в количестве 9...11 кг/1000 дал. 6. Композиция по п. 1, отличающаяся тем, что она содержит душистое вещество с ароматом земляники в количестве 9...10 кг/1000 дал. 7. Композиция ...

СПОСОБ ПРОИЗВОДСТВА ИГРИСТОГО ВИНА "ГУБЕРНАТОР"

Способ производства игристых вин, предусматривающий обработку и выдержку ассамбляжей шампанских виноматериалов, купажирование их, выдержку купажей, дезаэрацию, тепловую обработку купажей перед шампанизацией, приготовление бродильной смеси, шампанизацию, выдержку на холоде шампанизированного вина, дозирование экспедиционного ликера и розлив, отличающийся тем, что выдержку ассамбляжей шампанских виноматериалов осуществляют перед купажированием в течение 3 - 5 месяцев, а состав купажей устанавливают при следующем соотношении виноматериалов, дал на 1000 дал купажа: Алиготе - 400 - 500 Пиво - 200 - 300 Рислинг - 100 - 200 причем выдержку полученных купажей проводят в течение 3 - 5 месяцев.

СПОСОБ ПРОИЗВОДСТВА НАПИТКА ИГРИСТОГО ПИНО-ДОН

Изобретение может быть использовано в винодельческой промышленности. Способ производства напитка игристого предусматривает купажирование белого, розового или красного сока винограда сорта ПИНО с коньячным спиртом или коньяком до содержания спирта 8-9% об. и содержания сахара не менее 110 г/дм3. Полученный продукт подвергают брожению до содержания спирта 10-12% об. и содержания сахара 75-90 г/дм3 и разливают при давлении газа не менее 100 кПа. Изобретение обеспечивает повышение органолептических показателей напитка, дегустационный балл - от 8,64 до 9,16. 1 з.п. ф-лы, 2 табл.

СПОСОБ ПРОИЗВОДСТВА АЛКОГОЛЬНЫХ ГАЗИРОВАННЫХ НАПИТКОВ

Использование: в ликеро-водочной промышленности. Способ осуществляют следующим образом. Исходные компоненты алкогольного напитка купажируют. Затем купаж разделяют на два потока в соотношении 1:3, меньший из которых оклеивают, например бентонитом, а больший поток охлаждают до 10 - 15С и затем смешивают эти потоки, выдерживают смесь 20 - 24 часов и насыщают диоксидом углерода одним из известных способов, например в сатураторе, синхронно-смесительной установке, акратофорах.

СПОСОБ ПРОИЗВОДСТВА ГАЗИРОВАННЫХ НАПИТКОВ, СОКОВ ИЛИ ВИН

Использование: в пищевой промышленности. Сущность изобретения: способ предусматривает закрутку потока двуокиси углерода и его подачу в слой жидкого продукта при условии, что шаг закрутки потока меньше толщины слоя жидкого продукта в направлении подачи по меньшей мере в 5 раз, для растворения двуокиси углерода в жидком продукте.

СПОСОБ ПРОИЗВОДСТВА СЛАБОАЛКОГОЛЬНОГО ШИПУЧЕГО НАПИТКА

Способ производства слабоалкогольных шипучих напитков, включающий приготовление водно-спиртовой жидкости, сахарного сиропа, раствора пищевой кислоты, ввод ароматизатора, купажирование, выдержку купажа и насыщение двуокисью углерода, отличающийся тем, что на стадии купажирования в водно-спиртовую жидкость вводят предварительно приготовленную смесь сахарного сиропа, пищевой кислоты и ароматизатора, прочем соотношение готового напитка и смеси сахара, пищевой кислоты, ароматизатора в дал/кг составляет 1 : 0,103 - 0,09.

СЛАБОАЛКОГОЛЬНЫЙ НАПИТОК

... 1. Слабоалкогольный напиток, содержащий воду, вещество со сладким вкусом, этиловый спирт - ректификат и ароматизатор со вкусом и ароматом южных фруктов, отличающийся тем, что в качестве ароматизатора со вкусом и ароматом южных фруктов он содержит ароматизатор со вкусом и ароматом персика при следующем содержании ингредиентов на 1000 дм3 готового продукта: Вещество со сладким вкусом (в пересчете на сахар) - 70,00 - 100,00 кг, Ароматизатор со вкусом и ароматом персика - 0,01 - 3,50 кг, Спирт этиловый - ректификат - 52,0 - 93,8 дм3 Вода - Остальное 2. Напиток по п.1, отличающийся тем, что он дополнительно содержит замутнитель, предпочтительно, в количестве от 0,05 до 1,50 кг. 3. Напиток по п.1, отличающийся тем, что он дополнительно содержит лимонную кислоту, предпочтительно в форме моногидрата, в количестве 0,50 - 4,00 кг. 4. Напиток по п.1, отличающийся тем, что он дополнительно содержит ароматизатор "Тоник D 2088", предпочтительно, в количестве 0,0005 - 0,01 кг. 5. Напиток по п.1, отличающийся ...

РЕЗЕРВУАРНЫЙ СПОСОБ ПРОИЗВОДСТВА ВЫДЕРЖАННОГО ШАМПАНСКОГО

... 1. Резервуарный способ производства выдержанного шампанского, предусматривающий обработку ассамбляжей, приготовление купажа из виноматериалов, получение резурвуарного и экспедиционного ликера, который спиртуют коньячным спиртом со сроком выдержки не менее пяти лет и выдерживают не менее 180 суток, введение в купаж дрожжевой разводки и резервуарного ликера, обескислороживание и шампанизацию бродильной смеси, выдержку шампанизированного вина в системе резервуаров, дозирование экспедиционного ликера, фильтрацию вина, обработку холодом, отдых и повторную фильтрацию, отличающийся тем, что при приготовлении купажа используют виноматериалы сортов винограда Пино, Шардоне и Траминер при соотношении 1-3:2-3:1-2 в количестве не менее 60% купажа, выдержку шампанизированного вина осуществляют при температуре 12-15°С в течение не менее 180 суток, при этом в процессе выдержки предотвращают оседание дрожжей путем легкого барботирования 1-2 раза в месяц в течение 15-20 мин диоксида углерода при одновременном ...

СПОСОБ ПРОИЗВОДСТВА ИГРИСТЫХ ВИН В НЕПРЕРЫВНОМ ПОТОКЕ В ОДНОЕМКОСТНОМ ОДНОКАМЕРНОМ АППАРАТЕ

Изобретение относится к винодельческой промышленности, в частности к способам производства игристых вин в непрерывном потоке. Цель изобретения: интенсификация процессов шампанизации вина и улучшение качества готового продукта. Способ состоит в подаче бродильной смеси в нижнюю надконусную часть аппарата с рассеиванием ее по внутреннему периметру. Сформированное шампанизируемое вино с меньшей частью отработанных дрожжей направляют на автолиз. Обогащеннное продуктами автолиза и осветленное шампанизированное вино выводят в накопитель-охладитель для доработки и розлива в бутылки. Основную чсть отработанных дрожжей и кристаллы виннокаменной кислоты осаждают в конусное дно аппарата. Уплотненные осадки через каждые 8 - 10 суток выводят из аппарата без остановки непрерывного потока шампанизации вина.

СПОСОБ ПРОИЗВОДСТВА ШИПУЧИХ ПЛОДОВО-ЯГОДНЫХ ВИН

Установка для насыщения воды и напитков диоксидом углерода

... 1. УСТАНОВКА ДЛЯ НАСЬПЦЕНИЯ ВОДЫ И НАПИТКОВ ДИОКСИДОМ УГЛЕРОДА, содержащая соединенные между собой системой трубопроводов колонку деаэрации , насос деаэрированной воды, колонку насьщения с устройствами для подачи диоксида углерода от его источника в колонку для диспергирования газожидкостной смеси, струйную насадку, расположенную на трубопроводе перед колонкой насыщения и соединенную своим входом по воде с нагнетатальным патрубком .насоса деаэрированной воды, входом по диоксиду углурода - с полостью колонки насыщения в ее верхней .части, а выходом - с входом устройства для диспергирования газожйдкостной смеси. насос-дозатор, смесительный бачок и накопительную колонку, отличающаяся тем, что, с целью повышения степени насыщения воды и напитков диоксидом углерода и увеличения биологической стойкости полученных напитков, она снабжена ионизатором газа, установленным на трубопроводе подвода диоксида углерода к устройству для его подачи в колонку насыщения и соединенным своим входом с источником ...

Способ производства шампанского в непрерывном потоке

Изобретение относится к винодельческой промышленности, в частности к технологии производства шампанского. Целью изобретения является повышение бродильной активности дрожжей и улучшение качества готовой продукции. Поток ликера разделяют на две части, одну из которых вводят в бродильную смесь, которучю подвергают шампанизации, а вторую на стадию адаптации дрожжей к условиям шампанизации при этом вторую часть ликера вводят в количестве , обеспечивающем равную концентрацию сахара в дрожжевой разводке, поступающей после адаптации на шампанизацию , и в шампанизируемом вине Кроме того, при производстве белого шампанского одну часть резервуарного ликера вводят в бродильную смесь после обескислороживания . При производстве розового шампанского после шампанизации смешивают белое и красное шампанизированные вина в соотношении, обеспечивающем постоянные органолептические и физико-химические показатели. 2 з.п.ф-лы. 1 ил. ё ...

Способ смешивания шампанского с ликером

Способ производства дрожжей для шампанизации

Способ охлаждения шампанского вина в отстойниках

Аппарат для получения игристых вин

Линия для производства игристых вин

Декантатор с устройством для отбора осветленного шампанского

Способ производства выдержанных шампанских и игристых вин

Способ производства ликеров для шампанских вин

Способ производства шампанских вин в непрерывном потоке

Способ производства выдержанного шампанского в резервуаре

Использование: в винодельческой промышленности , в производстве шампанских вин. Способ предусматривает составление тиражной смеси, вторичное брожение и выдержку шампанских виноматериалов в резервуаре , смонтированном с возможностью вращения вокруг горизонтальной оси, причем вторичное брожение ведут один месяц при перемешивании 3-4 раза в день по 30 мин путем вращения резервуара, а выдержку проводят в течение пяти месяцев, при этом в течение четырех месяцев вино перемешивают 3-4 раза в день по 30 мин вращением резервуара, а на четвертом месяце выдержки вино нагревают до 30-35°С в течение 20-30 мин и охлаждают естественным путем до температуры окружающей среды. На пятом месяце выдержки вино оставляют в покое, выпавший осадок охлаждают и пускают на розлив через фильтр-пресс.

Способ производства безалкогольного напитка

Изобретение относится к безалкогольной промышленности. Целью изобретения является ускорение сбраживания, повышение биологической ценности и качества напитков. Способ предусматривает смешивание воды с яблочным соком, натуральным или концентрированным, сбраживание в герметичном резервуаре, добавление в процессе сбраживания после стадии размножения дрожжей ароматсодержащего компонента до обеспечения титруемой кислотности среды 3,0-4,0 г/дм3, после сбраживания вводят плодово-ягодные соки. В качестве ароматсодержащего компонента используют соки крыжовника или цидонии, или смородины. А из плодово-ягодных соков используют соки яблочный или смородиновый, или рябиновый, или клубничный, или малиновый. 3 з.п. ф-лы.

Способ получения игристого напитка

Изобретение относится к безалкогольной промышленности. Целью изобретения является повышение качества и снижение себестоимости. Проводят деалкоголизацию сухих виноматериалов или спиртованного сока, затем вносят сок при соотношении 1:1-4. Шампанизацию смеси проводят до снижения сахаристости на 1,8-2,0 г/см3при давлении 350-400 кПа, а перед шампанизацией вводят чистую культуру дрожжей из расчета 0,5-1,0 млн. дрожжевых клеток в 1 мл смеси. В процессе розлива можно добавить сок или сироп до содержания сахара в напитке 3,0-10,0 г/100 см3, а после розлива проводят бутылочную пастеризацию. 2 табл.

Способ производства игристого вина

Изобретение относится к винодельческой промышленности и касается способа производства игристого вина. Целью изобретения является повышение органолептических свойств готового продукта, упрощение и сокращение длительности процесса. Способ производства игристых вин предусматривает сбраживание бродильной смеси под давлением диоксида углерода, введение дрожжей, нагревание вина, выдержку, охлаждение его, введение экспедиционного ликера и фильтрацию. Дрожжи вводят непосредственно перед нагреванием вина, а экспедиционный ликер - после нагревания, при выдержке равномерно распределяют и ассимилируют ликер в вине, а охлаждение проводят до температуры от -4 до -6°С с одновременным дополнительным равномерным распределением ликера в вине и предварительной фильтрацией.

Аппарат для шампанизации вина в непрерывном потоке

АППАРАТ ДЛЯ ШАМПАНИЗАЦИИ ВИНА. В НЕПРЕРЫВНОМ ПОТОКЕ, содержащий вертикально установленный герметичный резервуар с патрубками для ввода бродильной смеси и отвода шампанизированного вина и расположенные в нем перегородки с образованием в зонах ввода бродильной смеси и отвода вина камер с насадкой, отличающийся тем, что, с целью повышения производительности, улучшения качества конечного продукта и упрощения конструкции аппарата, каждая нижняя перегородка камер с нас адкой выполнена так, что в вертикальном сечении имеет форму параболы вида , I о -ТТ где Vg - скорость потока вина в i центре аппарата; R - радиус резервуара; (Л г - расстояние от продольной оси резервуара.

Способ производства шипучих вин

Способ шампанизации вина в непрерывном потоке

СПОСОБ ИАМПАНИЗАЦИИ ВИНА В НЕПРЕРЬЮНОМ ПОТОКЕ, предусматривающий приготовление бродильной смеси и -вторичное сбраживание ее и выдержку на дрожжах, закрепленных на насадке , отличающийся тем, что, с целью улучшения органолептических свойств готового продукта и снижения его себестоимости, в качестве насадки используют пемзу.

Штамм дрожжей ди-4, используемый для производства мускатного игристого

Способ приготовления ликеров для производства шампанского

Способ производства красных игристых вин

Изобретение относится к виноделию, в частности к технологии производства игристых вин. Целью изобретения является повышение органолептических свойств готового продукта и его стабильности. В бродильную смесь вводят дрожжевую разводку, брожение осуществляют в потоке в течение 6-10 сут., затем часть шампанизируемого вина подвергают биогенерации в течение 5-7 сут. при 12-14°С, смешивают с другой частью потока для обеспечения содержания аминного азота 100-150 мг/л, а затем разделяют на два потока, один из которых охлаждают, а другой нагревают до 25-30°С, выдерживают при температуре нагрева 1-3 месяца и охлаждают. Охлажденные потоки фильтруют, вводят ликер, фильтруют и разливают вино.

Устройство для насыщения безалкогольных напитков диоксидом углерода

УСТРОЙСТВО ДЛЯ НАСЫЩЕНИЯ БЕЗАЛКОГОЛЬНЫХ НАПИТКОВ ДИОКСИДОМ УГЛЕРОДА, содержащее последовательно соединенные системой трубопроводов нагнетательный насос, смеситель в виде эжектора и накопительную емкость , отличающееся тем, что, с целью снижения расхода диоксида углерода, оно снабжено дополнительной камерой смешивания, расположенной на трубопроводе между нагнетательным насосом и накопительной емкостью , при этом эжектор установлен в дополнительной камере смешивания с возможностью совершения колебательного движения его горловины и диффузора, а в смесительной камере эжектора размещена регулировочная игла. (Л ю to О5 со ...

Способ производства игристых вин в непрерывном потоке и установка для его осуществления

... 1. Способ производства игристых вин в непрерывном потоке, предусматривающий подготовку бродильной смеси , шампанизацию ее в присутствии дрожжей путем подачи потока бродильной смеси в верхнюю часть первого по ходу процесса бродильного резервуара рассеиванием, перетока шампанизируемого вина во второй бродильный резервуар снизу вверх рассеиванием и биогенерацию его, отличающийся тем, что, с целью ускорения процесса шампанизации и повышения органолептических свойств готового продукта, в процессе шампанизации бродильной смеси в первом бродильном резервуаре на 1/3 его высоты поток перераспределяют с периферии резервуара, температуру шампанизируемого вина в донной части резервуаров поддерживают равной 3-4°С, а рассеивание потока во втором бродильном резервуаре осуществляют по его внутренней поверхности по линии . максимального поперечного сечения, причем по мере накопления в донной части второго бродильного резервуара дрожжевых осадков и солей виннокаменной кислоты их удаляют из резервуара , выдерживают ...

Способ производства хереса в потоке

Способ приготовления вин,насыщенных диоксидом углерода

СПОСОБ ПРИГОТОВЛЕНИЯ ВИН, НАСЫЩЕННЫХ ДИОКСИДОМ УГЛЕРОДА, предусматривающий приготовление бродильной смеси из обработанных сухих виноматериалов, введение резервуарного ликера и дрожжевой разводки, шампанизацию смеси, дозирование экспедиционным ликером и обработку холодом, отличающийся тем, что, с целью снижения себестоимости продукта и сокращения продолжительности процесса шампанизации, обработанные сухие виноматериалы перед введением резервуарного ликера диоксидом углерода до давления 0,22-0,25 МПа при 10-12°С, при этом резервуарньм ликер вводят в количестве , обеспечивающем 9-10 г/л саха (Л ра, а шампанизацию смеси осуществляют в течение 7-8 сут.

Способ производства газированного вина

СПОСОБ ПРОИЗВОДСТВА ГАЗИРОВАННОГО ВИНА, включающий пересыщение виноматериала углекислым газом, выдержку его в присутствии биомассы дрожжей, охлаждение, фильтрацию, дозирование ликера, вьщержку и розлив , отличающийся тем, что, с целью повышения стабильности газированного вина к биологическим помутнениям и улучшения его физико-химических свойств и типичных качеств, пересьпцение виноматериала углекислым газом осуществляют одновременно с вьдержкой его в присутствии биомассы дрожжей в две стадии, при этом на первой стадии пересыцение осуществляют при давлении 1,5-2,0 МПа и температуре 40-45 0 с последующим S сбросом давления до 0,4-0,5 МПа, а (Л на второй стадии процесс ведут в те ,чение 30-40 мин.

Способ производства шампанского

СПОСОБ ПРОИЗВОДСТВА ШАМПАЬ СКОГО, предусматривающий приготовление купажированного виноматериала, введение в него тиражного ликера и дрожжевой разводки, шампанизацию тиражной смеси, введение экспедиционного ликера и выдерживание, о т л ич ающи и ся тем, что, с цель улучшения органолептических показателей шампанского, экспедиционный ликер вводят в смеси .с этиловым эфиром линолевой кислоты при концентрации последнего в смеси 0,0005-0,01% в зависимости от марки шампанского, при этом количество вводимой смеси на 1 л шампанского составляет 4 i 160 мл. СУ) ...

Машина для дегоржажа шампанского и дозирования ликера

Способ производства газированного вина

Способ подготовки дрожжей и шампанизации

АППАРАТ ДЛЯ ШАМПАНИЗАЦИИ ВИНА В НЕПРЕРЫВНОМ ПОТОКЕ

Устройство для контрольной выдержки шампанского в бутылках

Carbonated tonic wine

A process for obtaining a carbonated tonic wine comprising the following steps: (a) contacting at least one herb with a solvent to extract a prophylactic and/or therapeutically effective constituent thereof; (b) mixing the extract from step (a) with a wine base; (c) mixing the product of step (b) with water to form a wine having an alcohol by volume (ABV) content of at least 1%; and (d) carbonating the product of step (c) using carbon dioxide. The at least one herb may be selected from the group of Marigold, Chamomile, Hawthorn, Horsetail, Cleavers, Devil’s Claw, St John’s Wort, Melissa, Passionflower, Plantain, Skullcap, Lime Flowers, Damiana, Vervain, Sweet Violet, Heartsease, Mistletoe, Astragalus, Damascen Rose and Milk Thistle. The solvent may be an alcohol, particularly wherein the solvent has an ABV of about 25-75%. The alcohol may be ethanol. Products of the method are disclosed to be carbonated tonic wines having an ABV content of at least 1%.

PROCESS FOR THE FLAVOUR AND/OR THE MOUSSEUX OF SPARKLING WINES SO PRODUCED

VERFAHREN ZUR VERBESSERUNG VON AROMA UND MOUSSEUX VON SCHAUMWEIN, SEKT ODER PERLWEIN

PROCEDURE FOR THE PRODUCTION OF FOAM WINE.

BIOCATALYST AND PROCEDURE FOR ITS PRODUCTION.

PROCEDURE AND EQUIPMENT FOR TRANSFERRING AND PROPORTIONING BRITTLE PARTICLES WITH HIGH RHYTHM E.G. FOR BRINGING INTO A CONTAINER.

PROCEDURE FOR THE PRODUCTION OF IMMOBILIZED YEASTS.

Method for culturing micro-organisms in reducing conditions obtained by a gas stream

METHOD AND DEVICE FOR PRODUCING SPARKLING ALCOHOL-CONTAINING BEVERAGES

A beverage

METHOD FOR CULTURING MICRO-ORGANISMS IN REDUCING CONDITIONS OBTAINED BY A GAS STREAM

La présente invention concerne un procédé de culture de micro-organismes permettant d'abaisser le potentiel d'oxydoréduction du milieu de culture, caractérisé en ce que l'on effectue ladite culture en conditions réductrices obtenues par un gaz réducteur comparé à l'air comprenant de l'hydrogènie et/ou de l'azote. Elle concerne encore un tel procédé pour modifier les flux métaboliques lors de la culture des micro-organismes. Elle s'applique plus particulièrement au domaine alimentaire et notamment à la production de boissoins alcoolisées.

PROCESS FOR THE PREPARATION OF IMMOBILIZED YEASTS

... 23443-415 A process for the preparation of yeasts immobilized in calcium alginate beads is disclosed. According to the process, yeast cells in a sodium alginate solution are added dropwise to a CaC12 solution, hardened in this solution for 30 to 180 minutes, washed for 100 to 500 minutes at 5 to 35.degree.C with water having a salt content of up to 0.5 g/l and then dried at 10 to 50.degree.C. The immobilized yeast are useful in production of alcoholic drinks, in particular in the fermentation of sparkling wine, without producing turbidity caused by the formation of calcium tartarate and calcium maleate crystals or dullness caused by leached yeast cells.

Intensive Gährträger with firm base

Procédé de fabrication de vins mousseux.

Verfahren zur Herstellung von Dispersionen aus Extrakten vegetabilischer Herkunft.

Procédé de préparation d'une boisson de saveur piquante.

Verfahren und Vorrichtung zur Herstellung von Schaumwein

Verfahren zur kontinuierlichen Herstellung von Schaumweinen und Anlage zu dessen Durchführung

Procédé pour la fabrication de vins mousseux

Verfahren der Sektbereitung im kontinuierlichen Fluss und Anlage zur Durchführung des Verfahrens

Procédé pour imprégner un vin ou autre liquide aqueux de gaz carbonique ou d'un autre gaz

Procédé pour l'obtention d'un vin effervescent

Verfahren und Vorrichtung zur kontinuierlichen Behandlung von Flüssigkeiten mit Enzymträgern

METHOD FOR PREPARATION OF SPARKLING WINE

СПОСОБ ПРОИЗВОДСТВА РОЗОВОГО ИГРИСТОГО ВИНА «НОВОСВЕТСКИЙ СЕРДОЛИК»

Изобретение относится к способам производства игристых вин, в частности высококачественных игристых вин, насыщенных углекислотой эндогенного происхождения. Способ предусматривает шампанизацию виноматериалов бутылочным методом с дозированием шампанизированного вина экспедиционным ликером.

СПОСОБ ПРОИЗВОДСТВА СУХОГО БЕЛОГО ГАЗИРОВАННОГО ВИНА "АРКАДИЯ ИСКРИСТАЯ"

Способ производства сухого белого газированного вина, который предусматривает купажирование обработанных сухих виноматериалов сорта Ркацители с мистелем, охлаждение, фильтрацию, насыщение купажа двуокисью углерода и разлив газированного вина, причем дополнительно используют сухие виноматериалы сорта Алиготе, при этом купажирование виноматериалов сортов Алиготе и Ркацители осуществляют в соотношении 7:3, а мистель готовят из винограда сорта Алиготе и / или сорта Ркацители.

СПОСОБ ПРОИЗВОДСТВА НАТУРАЛЬНЫХ ИГРИСТЫХ ВИН, ОБОГАЩЕННЫХ ФРУКТАМИ ИЛИ ЯГОДАМИ

Изобретение относится к винодельческой промышленности, а именно к производству вина «Игристое» ("Spumant natural"), обогащённого натуральными фруктами или ягодами. Согласно предложенному методу предусматривается обработка виноматериалов, приготовление тиражного и экспедиционного ликёров, составление тиражной смеси, проведение вторичного брожения в герметичных резервуарах под давлением углекислого газа, охлаждение и фильтрация сброженной смеси, выдержка в/м на фруктовом или ягодном сырье, в результате которой происходит обогащение ароматическими и экстрактивными компонентами, а также микроэлементами и витаминами, внесение экспедиционного ликёра (по необходимости), грубая фильтрация с целью сохранения некоторой части тонкого осадка фруктового или ягодного наполнителя для продолжения экстракции ароматического комплекса и после розлива и изобарический розлив. Результатом служит возможность использования в качестве сырья, содержащего ароматические и экстрактивные вещества, натуральные фрукты ...

СПОСОБ ПРОИЗВОДСТВА ШАМПАНСКОГО КОЛЛЕКЦИОННОГО БРЮТ, СУХОГО, ПОЛУСУХОГО "НОВЫЙ СВЕТ"

Способ производства шампанского коллекционного брют, сухого, полусухого, который включает приготовление, обработку и ассамбляж виноматериалов, купажирование, приготовление тиражной смеси, разлив ее в бутылки и брожение в бутылках, послетиражную выдержку, ремюаж и декордаж, введение экспедиционного ликера, контрольную выдержку, причем используют виноматериалы шампанские, изготовленные из винограда сортов Шардоне, Рислинг рейнский, Пино белый, Пино серый, Пино черный, Алиготе, Каберне Совиньйон, выращенных в Автономной республике Крым, при приготовлении тиражной смеси в купаж добавляют дрожжевую разводку из расчета не менее 1млн./см3 дрожжевых клеток и концентрацией не менее 80 млн. клеток/см, при этом разводку чистой культуры дрожжей готовят с применением шампанской расы Ш-7 НС вида Saccharomyces vini.

ШТАММ МОЛОЧНОКИСЛЫХ БАКТЕРИЙ LEUCONOSTOC OENOS L-04 - ДЛЯ БИОЛОГИЧЕСКОГО КИСЛОТОПОНИЖЕНИЯ КРАСНЫХ СТОЛОВЫХ ВИНОМАТЕРИАЛОВ

Штамм молочнокислых бактерий, который заявляется, получен впервые из виноматериала Каберне высокого качества. Штамм молочнокислых бактерий Leuconostoc oenos L-04 имеет повышенную кислотопонижающую способность и обеспечивает образование минимального количества летучих кислот при яблочно-молочном брожении. Вышеуказанный штамм хранится в коллекции микроорганизмов для виноделия Национального института винограда и вина «Магарач» и депонирован в коллекции промышленных микроорганизмов Института микробиологии и вирусологии им. Заболотного НАНУ, г. Киев.

СПОСОБ ПРОИЗВОДСТВА КРАСНОГО ИГРИСТОГО ВИНА "ГЕОРГИЕВСКОЕ"

Изобретение относится к винодельческой промышленности. Способ предусматривает купажирование шампанских виноматериалов и марочных вин, шампанизацию купажа. При купажировании используют виноматериалы сортов винограда Каберне, Рубиновый Магарач, Мерло, Пино черный и 20-40% марочных вин.

Process for production of wines containing carbon dioxide

Process for production of sparkling wines

СПОСОБ И УСТРОЙСТВО ДЛЯ ПОЛУЧЕНИЯ ШИПУЧИХ АЛКОГОЛЬСОДЕРЖАЩИХ НАПИТКОВ

Способ сводится либо к приготовлению предварительно стабилизированной или нестабилизированной исходной смеси, которую подвергают направленному спиртовому брожению, либо к приготовлению предварительно стабилизированного или нестабилизированного алкогольсодержащего нешипучего напитка, который подвергают карбонизации. Каждый из этих процессов осуществляют отдельно, и давление в герметичных системах постоянно с момента завершения брожения на протяжении хранения, транспортировки и потребления в случае первого процесса и на протяжении карбонизации, хранения, транспортировки и потребления в случае второго процесса. Устройство состоит из емкости (1) с верхней (14) и нижней (15) концевыми частями. В центре верхней концевой части (14) установлена многофункциональная пробка-головка (3). Нижний открытый конец трубы (4) находится почти вплотную к нижней концевой части (15). Внутри трубы (4) герметично установлен сменный фильтр (5), изготовленный из материала с размером пор до 100 мкм. Международная ...

ЛИНИЯ ДЛЯ ПРОИЗВОДСТВА ИГРИСТОГО ВИНА

Линия для производства игристого вина включает резервуар для купажа, дрожжевой аппарат, резервуар с наполнителем для биологического удаления кислорода из купажа, цистерну для выдержки купажа, цистерны для резервуарного и экспедиционного ликеров, теплообменник-пастеризатор, резервуар для тепловой выдержки купажа, теплообменник-охладитель пастеризованного купажа, бродильный аппарат, аппарат с наполнителем для биогенерации игристого вина, теплообменник-охладитель игристого вина, термос-резервуар с наполнителем, приемный аппарат, трубопроводы, фильтр-прессы, гравитационно-диффузионные резервуары-перемешиватели, дозаторы, электродиализную установку.

СПОСОБ ПРОИЗВОДСТВА ВИНА ИГРИСТОГО КРАСНОГО ВЫДЕРЖАННОГО "КРЫМСКОЕ ИГРИСТОЕ"

Способ производства вина игристого красного выдержанного, который включает приготовление, обработку и ассамбляж виноматериалов, купажирование, приготовление тиражной смеси, разлив ее в бутылки и брожение в бутылках, послетиражную выдержку, введение экспедиционного ликера, причем используют виноматериалы шампанские, изготовленные из винограда сортов Каберне, Саперави, Мерло, Матраса, Хиндогни, Пино фран, выращенных в Автономной Республике Крым. При приготовлении тиражной смеси в купаж добавляют дрожжевую разводку. При этом разводку чистой культуры дрожжей готовят с применением шампанской расы вида Saccharomyces vini.

ЛИНИЯ ДЛЯ ПРОИЗВОДСТВА ИГРИСТОГО ВИНА

Линия для производства игристого вина в непрерывном потоке включает резервуар для купажа, дрожжевой аппарат, резервуар с наполнителем для биологического удаления кислорода из купажа, цистерну для купажа, цистерны для резервуарного и экспедиционного ликеров, теплообменник-пастеризатор, резервуар для тепловой выдержки купажа, теплообменник-охладитель пастеризованного купажа, бродильный аппарат, аппарат с наполнителем для биогенерации игристого вина, теплообменник-охладитель игристого вина, термос-резервуар с наполнителем, приемный аппарат, трубопроводы, фильтр-прессы, гравитационно-диффузионные резервуары-перемешиватели, дозаторы. Также после резервуара для купажа установлено электродиализную установку. После резервуара для выдержки купажа установлено смеситель потоков купажа и ликера. Перед бродильным аппаратом периодического сбраживания установлен теплообменник-подогреватель-охладитель с дополнительной секцией догревания игристого вина до температуры брожения. После секции догревания теплообменника-подогревателя ...

ЯБЛОЧНОЕ СТОЛОВОЕ ИСКРИСТОЕ ВИНО " СЕРПАНОК "

Яблочное столовое искристое вино содержит сухой яблочный виноматериал и водно-спиртовой настой чабреца. Изобретение относится к винодельческой промышленности, в частности, к столовым шипучим ароматизированным винам.

СПОСІБ ВИРОБНИЦТВА ПЕРЛОВОГО ВИНА

Спосіб виробництва перлового вина, при якому до складу тиражної суміші додатково вводять натуральний яблучний або грушевий екстракт в кількості 10-15 % від об'єму, при цьому вторинному бродінню піддають бродильну суміш, заздалегідь штучно насичену СО2 до 190-210 кПа.

СИСТЕМА ДЛЯ РЕМЮАЖУ ШАМПАНСЬКИХ ВИН

Система для ремюажу шампанських вин містить основу зі стояками та щонайменше одну поворотну платформу, розміщену на валу та виконану у вигляді диска з отворами, в кожному з яких розміщено контейнер для пляшки та привід. Контейнер для пляшки виготовлений у вигляді футляра, спорядженого буртиком на зовнішньому боці. Платформи розміщено по краях вала, який у середній частині взято у підшипники, установлені у подвійному стояку, який закріплено на основі і на який установлено опорний Т-подібний кронштейн з роликами по краях, кожен з яких упирається у відповідний диск у верхній його частині, а на основі змонтовано опорні ролики з ребордами, на які опираються платформи. Система для ремюажу у порівнянні з прототипом має меншу енергоємність та металомісткість при високій надійності роботи і зручності її експлуатації та можливості контролю ремюажу на будь-якій стадії процесу для одержання високої якості вина.

СПОСІБ ТА ВУЗОЛ ДОЗУВАННЯ РЕЗЕРВУАРНОГО АБО ЕКСПЕДИЦІЙНОГО ЛІКЕРУ В ПОТІК КУПАЖУ АБО ІГРИСТОГО ВИНА, СПОСІБ ПІДТРИМАННЯ ВЕЛИЧИНИ ВИТРАТИ РЕЗЕРВУАРНОГО ЛІКЕРУ ТА СПОСІБ ПІДТРИМАННЯ ВМІСТУ ЦУКРУ В ПОТОЦІ ІГРИСТОГО ВИНА

Спосіб та вузол дозування резервуарного або експедиційного лікеру в потік купажу або ігристого вина при безперервному способі виробництва ігристого вина, спосіб підтримання величини витрати резервуарного лікеру та спосіб пітримання вмісту цукру в потоці ігристого вина належать до виноробної промисловості, зокрема до виробництва ігристих вин безперервним способом. Спосіб дозування включає дозовану подачу резервуарного або експедиційного лікеру в потік купажу або ігристого вина з подальшою подачею суміші в приймальну ємність. Тиск уприскування резервуарного або експедиційного лікеру в потік купажу або ігристого вина відповідає заданому об'єму витрати купажу або концентрації цукру в ігристому вині, а тиск потоків купажу або ігристого вина і резервуарного або експедиційного лікеру, які подаються на змішування, підтримують постійним за допомогою насосів з керованою продуктивністю. Дозовану подачу резервуарного або експедиційного лікеру здійснюють шляхом його уприскування в потік купажу або ігристого ...

Method To Reduce Biogenic Amine Content in Food

This invention relates to a method of reducing biogenic amine content in a beverage by contacting the beverage and/or beverage intermediate with an enzyme having transglutaminase activity. 1. A method of reducing biogenic amine content in a beverage comprising contacting the beverage and/or beverage intermediate with an enzyme having transglutaminase activity.2Streptomyces.. The method according to wherein the enzyme having transglutaminase activity is obtainable from3. The method according to wherein the biogenic amine is selected from tyramine claim 1 , histamine and combinations thereof.4. The method according to wherein the contacting is done in the presence of peptide bound glutamine.5. The method according to wherein the contacting is done in the absence of peptide bound glutamine.6. The method according to wherein at least 50% of the biogenic amine is reduced.7. The method according to wherein the beverage has a protein content less than 5% (w/w).8. The method according to wherein the beverage is wort.9. The method according to wherein the beverage is alcoholic.10. The method according to wherein the alcoholic beverage is beer.11. The method according to wherein the alcoholic beverage is wine.12. The method according to wherein the contacting is done at pH 3.0-6.5.13. The method according to wherein concentration of the enzyme having transglutaminase activity used is about 0.1 mg to about 1000 mg enzyme protein (EP) per liter of beverage or beverage intermediate.14. (canceled)15. A beverage having low content of biogenic amines obtained by a method of . This invention relates to a method of reducing the content of biogenic amines in food. More particularly, this invention relates to a method of reducing biogenic amines in low protein food, for example, beverages like wine and beer. Even more particularly, this invention relates to the use of enzymes having transglutaminase activity to reduce the content of biogenic amines in low protein food, for example, ...

Binding ligand linked drug delivery conjugates of tubulysins

Described herein are compounds, pharmaceutical compositions, and methods for treating pathogenic cell populations. Kits including the compounds or pharmaceutical compositions are described. The compounds described herein include conjugates of tubulysins and folates. The conjugates also include a releasable bivalent linker.

INTERMODAL TRANSPORT PLATFORM

A collapsible intermodal transport platform and methods for its operation are disclosed. The invention comprises first braces that rotate about a mounting point on the frame that supports a cargo loading surface. The first braces are positioned along the platform so as to provide lifting and stacking fitments at the standard overhead crane lifting points when in a lift configuration. The first braces may be rotated inboard down to the loading surface, thereby presenting stacking blocks at the crane lifting points for stacking several platforms together. Second braces attach to the first braces to assist in load distribution. The frame may comprise center feet extensions to further assist in load distribution. Other features and aspects disclosed lend to the invention's low weight and high carrying capacity, as well as its unique load securing features. 1. A transport platform comprising:a loading surface having two ends and two sides and a centerline equidistant between the two ends;a frame disposed beneath the loading surface;two first braces on each of the two sides of the loading surface, each first brace having a first end attached to the frame at a first distance from the centerline of the loading surface, and a second end extending from and rotatable about the first end; andtwo second braces on each of the two sides of the loading surface, each second brace having a proximal end attached to the second end of one of the first braces, and a distal end extending from the proximal end;wherein, when the transport platform is placed in a stowed position, the second end of each first brace is proximate to the loading surface and the distal end of each second brace extends from the first brace toward the centerline of the loading surface;and wherein, when the transport platform is placed in a lift position, the second end of each first brace extends away from the loading surface and the distal end of each second brace is attached to the frame at a distance from the ...

Rhamnose and forssman conjugated immunogenic agents

The present invention provides an immunogenic composition comprising a T-cell antigen in association with a rhamnose monosaccharide and/or Forssman disaccharide, and corresponding methods for inducing immune response. The T-cell antigen may be for example, a tumor vaccine, such as a tumor cell or one or more tumor antigens. The invention takes advantage of the naturally high titers of anti-Rhamnose and/or anti-Forssman disaccharide in humans to target vaccine compositions to antigen presenting cells.

Topical ocular drug delivery

The present invention provides compositions and methods for increasing the delivery (i.e., bioavailability) of a compound to an ocular cell. Such compositions and methods can be used to treat an ocular clinical condition. Typically, increased bioavailability or delivery of the compound to ocular cells is achieved by utilizing a membrane transporter.

SYSTEMS AND METHODS FOR BLOOD RECOVERY FROM ABSORBENT SURGICAL MATERIALS

Systems and methods are described for salvaging red blood cells from patients during a surgical procedure. In one general aspect, a system is described for extracting blood from blood-soaked absorbent surgical materials such as surgical sponges, gauze, tape, and the like. The collected blood and fluids from these materials can be transferred to a cell salvage machine for harvesting viable red blood cells for autotransfusion. 1. An assembly for extracting blood from absorbent material , comprising:a basin having a wall and floor; anda perforated apparatus adapted to be disposed within the basin, wherein the perforated apparatus allows blood to pass therethrough from the absorbent material into the remainder of the basin for collection and reuse.2. The assembly of claim 1 , further comprising a plunger plate that is sized to be inserted into the basin claim 1 , wherein the plunger plate is adapted to compress the absorbent materials to extract blood therefrom.3. The assembly of claim 2 , wherein the plunger plate is driven down by rotation of a shaft.4. The assembly of claim 1 , further comprising a rinse solution that is applied to the absorbent material to assist in extracting the blood.5. The assembly of claim 4 , wherein the rinse solution is initially applied to a plunger plate.6. The assembly of claim 1 , wherein the perforated apparatus is adapted to be rotated to allow blood absorbed in absorbent material to be extracted using centrifugal force.7. The assembly of claim 1 , wherein the perforated apparatus is mounted on stands that extend from the floor of the basin.8. The assembly of claim 1 , wherein the floor of the basin is concave or conically shaped in order to direct blood to an exit port of the basin.9. The assembly of claim 8 , wherein the exit port connects to tubing leading to a cell salvage machine.10. The assembly of claim 1 , wherein the perforated apparatus comprises a second basin and wherein the first basin and second basin are configured to ...

METHOD, APPARATUS AND UNIVERSAL CONTAINER FOR NATURAL CARBONATION OF BEVERAGES

The present invention relates to a method, apparatus and universal container for natural carbonation of beverages, which will be used in the food industry, in particular in the production of beer, sparkling wines and carbonated fruit drinks. The method of naturally occurring carbonation of beverages involves the operations of feeding with fermenting substrate, adding water, adding yeast, fermenting the resulting liquid mixture. The fermentation is carried out in a specialized container at an optimum temperature of 8° C. to 23° C., depending on the yeast species. The fermentation process lasts for 3 to 4 days and is accompanied by an increase in container pressure to 2 bar. 1. A method for natural carbonation of beverages comprising the operations:feeding with substrate for fermentation,addition of water,addition of yeast,fermentation of the resulting liquid mixture, characterized in that the fermentation is carried out in a specialized container at an optimum temperature of 8° C. to 23° C. depending on the type of yeast, wherein the fermentation process lasts 3-4 days, accompanied by an increase in container pressure to 2 bar; wherein the method also includescooling the fermented liquid mixture from 23° C. to 12° C.-0° C.;saturation of the fermented liquid mixture with fermentation carbon dioxide.2. The method for natural carbonation of beverages according to claim 1 , wherein the specialized container is a universal container equipped with a membrane expansion container.3. An apparatus for naturally carbonated beverages for natural carbonation of beverages claim 1 , comprising:a container having a cylindrical body with a conical portion at one end, the container being provided with temperature and pressure sensors, wherein the container is placed in a refrigeration chamber provided with a double bottom in which a refrigeration unit is provided, wherein the conical part of the container is formed as a truncated cone in whose small base the opening of the container ...

PALLET CONTAINER

A pallet container for storing and for transporting a liquid filling material includes a base pallet, a lattice frame fastened thereon and made of metal bars, and a fabric cover suspended in the lattice frame and accommodating a liquid-tight inliner composed of a plastics film and/or metal foil for receiving the liquid filling material. The inliner arranged within the cube-shaped fabric cover is designed, for gas-assisted emptying, as a double chamber inliner with a rear chamber for blowing in compressed air or gas and a front chamber for receiving the liquid filling material. A film or foil separating wall located in-between avoids the sensitive filling material from directly contacting the blown-in compressed air. 114-. (canceled)15. A pallet container for storing and transporting an aseptic liquid filling material , comprising:a base pallet;a lattice frame fastened on the base plate and made of metal bars;a fabric cover suspended in the lattice frame;a liquid-tight inliner arranged within the fabric cover and configured to automatically unfold when filling the liquid filling material, said inliner being composed of a plastics film and/or metal foil and including a base-side filling and removal connection piece, said inliner being configured for gas-assisted emptying and having a first chamber for blowing in compressed air and a second chamber for receiving the liquid filling material, said second chamber having a front side in communication with the base-side filling and removal connection piece;a thin, stiff base plate which is arranged within the fabric cover below the inliner and to which the inliner is fixed;a connection piece provided on an upper side of the inliner for attachment of a compressed air line in communication with the first chamber; anda filling and removal fitting placed upon the filling and removal connection piece and fastened to a lower area of the lattice frame.16. The pallet container of claim 15 , wherein the fabric cover has a cube- ...

OLIGOMERS

Certain disclosed oligomers induce exon skipping during processing of myostatin pre-mRNA. The oligomers may be in a vector or encoded by the vector. The vector is used for inducing exon skipping during processing of myostatin pre-mRNA. A therapeutically effective amount of the oligomer may be administered to a subject patient such that exon skipping during processing of myostatin pre-mRNA is induced. The administration to a subject may be used in order to increase or maintain muscle mass, or slowing degeneration of muscle mass in the subject. The administration to a subject may ameliorate muscle wasting conditions, such as muscular dystrophy. Examples of such muscular dystrophies which may be so treated include Becker's muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy, myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy. 2. The oligomer of claim 1 , wherein the oligomer causes an exon skipping rate of at least 58 40%.3. The oligomer of claim 1 , wherein the oligomer causes an exon skipping rate of at least 90%.4. (canceled)5. The oligomer of claim 1 , wherein the oligomer is a phosphorodiamidate morpholino oligonucleotide (PMO).6. The oligomer of claim 1 , wherein the oligomer is between 20 and 40 bases in length.7. The oligomer of claim 1 , wherein the oligomer is about 30 bases in length.8. The oligomer of claim 1 , wherein the base sequence is selected from SEQ ID NOS. 4-6-8.9. The oligomer of claim 1 , wherein the base sequence is selected from SEQ ID NOS. 4-4 11 claim 1 , 12 claim 1 , 14 claim 1 , and 15.10. (canceled)11. (canceled)12. The oligomer of claim 1 , wherein the oligomer is conjugated to or complexed with a distinct chemical entity.13. A vector for inducing exon skipping during processing of myostatin pre-mRNA claim 1 , the vector encoding an oligomer of claim 1 , ...

RNAi Therapy for Hepatitis B Virus Infection

Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hepatitis B virus gene are described. Pharmaceutical compositions comprising one or more HBV RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi triggers to infected liver in vivo provides for inhibition of HBV gene expression and treatment. 1. A composition for inhibiting expression of a hepatitis B virus gene comprising:{'sub': 'x', 'claim-text': MLP is a melittin-like peptide,', {'sub': 3', '3, '-L-T has the structure represented by —CO—C(CH)═C(T)-COOH or —CO—C(T)=C(CH)—COOH, wherein T comprises a targeting ligand having affinity for the an asialoglycoprotein receptor, and'}, 'x is greater than 80% of the number of primary amines on MLP in a population of MLPs,, 'a) MLP-(L-T)wherein'}b) a first HBV RNAi trigger comprising an antisense strand and a sense strand wherein the antisense strand comprises nucleotides 2-18 of any of the antisense sequences provided in Table 1A, andc) a second HBV RNAi trigger comprising an antisense strand and a sense strand wherein the antisense strand comprises nucleotides 2-18 of any of the antisense sequences provided in Table 1A.2. The composition of claim 1 , wherein the first HBV RNAi trigger comprises a sense strand comprising nucleotides 2-18 of any of the corresponding sense sequences provided in Table 1B claim 1 , and the sense strand is optionally linked to a targeting group; and the second RNAi trigger comprises a sense strand comprising nucleotides 2-18 of any of the corresponding sense sequences provided in Table 1B claim 1 , and the sense strand is optionally linked to a targeting group.3. The composition of claim 1 , wherein the first HBV RNAi trigger comprises a sense strand covalently linked to a cholesteryl group via a TEG group claim 1 , and the second HBV RNAi ...

EXPRESSION VECTOR DELIVERY SYSTEM AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE

Embodiments of a novel system for delivering an expression vector encoding an antigen to a subject that allows for spatiotemporal control over stimulation of the subject's immune response to the antigen are provided. In some embodiments, the expression vector delivery system includes a polymer linked to an adjuvant in prodrug form that can form polymer nanoparticles and enter a cell (such as an immune cell) under physiological conditions. In some embodiments, the adjuvant is linked to the polymer by an enzyme degradable labile bond, the cleavage of which activates the adjuvant to stimulate an immune response. 1. A polymer linked to an adjuvant prodrug , wherein:the polymer linked to the adjuvant prodrug forms polymer nanoparticles that enter immune cells under physiological conditions, andthe adjuvant of the adjuvant prodrug comprises a functional moiety for adjuvant activity that is masked by linkage to a linker connected to the polymer,the linker comprises an enzyme-degradable labile bond, andcleavage of the enzyme-degradable labile bond by an intracellular enzyme unmasks the functional moiety and releases an active adjuvant.2. The polymer linked to the adjuvant prodrug of claim 1 , wherein the enzyme is a cathepsin.3. The polymer linked to the adjuvant prodrug of claim 1 , wherein the linker comprises a cathepsin-cleavable peptide comprising L-amino acids or D-amino acids comprising the amino acid sequence set forth as one of: KPLR (SEQ ID NO: 2) claim 1 , KLRP (SEQ ID NO: 3) claim 1 , SLVR (SEQ ID NO: 4) claim 1 , or SLRV (SEQ ID NO: 5) claim 1 , and cathepsin cleavage of the peptide cleaves the labile bond and activates the adjuvant.4. The polymer linked to the adjuvant prodrug of claim 1 , wherein the adjuvant prodrug comprises a toll-like receptor (TLR) agonist claim 1 , a Stimulator of Interferon Genes (STING) agonist claim 1 , a C-type lectin receptor (CLR) agonist claim 1 , a RIG-I-like receptor (RLR) agonist claim 1 , or a NOD-like receptor (NLR) agonist. ...

Flavor System and Method for Making Sherry Wine Like Beverages

A method of making a sherry wine-like beverage includes combining water, ethanol and a plurality of flavor compounds in an amount sufficient to impart the flavor of a sherry wine without the need for fermentation and/or aging. 136-. (canceled)37. A kit for making a sherry wine-like beverage , the kit including:a flavor system having a quantity of each of a plurality of flavor compounds, the plurality of flavor compounds including at least one cheesy, sweaty aroma flavor compound; at least one malty, buttery and/or sweet aroma flavor compound; at least one floral and/or honey aroma flavor compound; at least one fruity aroma flavor compound; at least one smoky, coconut, woody aroma flavor compound; at least one cooked, seasoning, fatty aroma flavor compound; and at least one phenolic/medicinal aroma flavor compound;wherein the plurality of flavor compounds can be combined in amounts sufficient to form different sherry wine-like beverages when added to a predetermined quantity of an aqueous solution.38. The kit of claim 37 , further including:(a) a container sized to contain the flavor system and a predetermined quantity of an aqueous solution;(b) instructions for combining the plurality of flavor compounds in different combinations and/or quantities with a predetermined quantity of an aqueous solution to form different sherry wine-like beverages;(c) a quantity of dearomatized wine solutions and/or powders;(d) a quantity of an aqueous solution comprising a mixture of water, ethanol, and optional colorants;(e) a quantity of sugar; and/or(f) a quantity of ethanol.39. The kit of claim 37 , wherein the plurality of flavor compounds further include a quantity of at least one sour taste flavor compound; a quantity of at least one sweet taste flavor compound; a quantity of at least one salty and bitter taste flavor compound; and/or a quantity of at least one astringent claim 37 , mouth feel flavor compound.40. The kit of claim 37 , wherein:the at least one at least one cheesy ...

DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE

The present application provides bifunctional compounds of Formula X or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as protein degradation inducing moieties for Bruton's tyrosine kinase (BTK). The present application also relates to methods for the targeted degradation of BTK through the use of bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to BTK which can be utilized in the treatment of disorders modulated by BTK. 2. The bifunctional compound of claim 1 , wherein the Targeting Ligand is of Formula TL-I.3. The bifunctional compound of claim 2 , wherein Ris (C-C) alkyl.48.-. (canceled)9. The bifunctional compound of claim 2 , wherein B is phenyl or pyridinyl.1012.-. (canceled)14. The bifunctional compound of claim 1 , wherein the Targeting Ligand is of Formula TL-II.15. The bifunctional compound of claim 14 , wherein Ris (C-C) alkyl.1619.-. (canceled)20. The bifunctional compound of claim 14 , wherein B is phenyl or pyridinyl.2123.-. (canceled)25. (canceled)26. The bifunctional compound of claim 1 , wherein the Targeting Ligand is of Formula TL-III.2736.-. (canceled)3839.-. (canceled)4243.-. (canceled)4547.-. (canceled)4961.-. (canceled)62. A pharmaceutical composition comprising a therapeutically effective amount of the bifunctional compound of claim 1 , or a stereoisomer or pharmaceutically acceptable salt thereof claim 1 , and a pharmaceutically acceptable carrier.63. A method of inhibiting or modulating the amount of Burton's tyrosine kinase (BTK) claim 1 , comprising administering to a subject in need thereof an effective amount of a compound of .64. A method of treating cancer or a proliferation disease in which BTK plays a role claim 1 , comprising administering to a subject in need thereof an effective amount of a compound of .65. (canceled)66. The method of claim 64 , wherein the cancer is lung cancer ...

CYCLIC NUCLEIC ACID MOLECULE HAVING GENE EXPRESSION CONTROL FUNCTION

The present invention aims to provide a nucleic acid molecule having improved stability in serum and capable of exhibiting a gene expression regulation function after transfer into the cell. A cyclic nucleic acid molecule represented by the following formula (A): 2. The nucleic acid molecule according to claim 1 , wherein X claim 1 , X claim 1 , Y claim 1 , Y claim 1 , Z-Zand W-Ware each independently a ribonucleotide residue or deoxyribonucleotide residue optionally modified by a methyl group.4. The nucleic acid molecule according to claim 1 , wherein at least one of X claim 1 , X claim 1 , Y claim 1 , Y claim 1 , Z-Zand W-Wis independently a ribonucleotide residue or deoxyribonucleotide residue optionally modified by a methyl group.5. The nucleic acid molecule according to wherein at least five of X claim 1 , X claim 1 , Y claim 1 , Y claim 1 , Z-Zand W-Ware each independently a ribonucleotide residue or deoxyribonucleotide residue optionally modified by a methyl group.6. The nucleic acid molecule according to comprising a polynucleotide strand comprising a guide strand claim 1 , a passenger strand and a linker claim 1 , and a double stranded structure formed in a part thereof claim 1 , wherein both ends of the double stranded structure are blunt ends.7. A composition for inhibiting expression of a target gene claim 1 , comprising the nucleic acid molecule according to .8. A pharmaceutical composition comprising the nucleic acid molecule according to .9. A method for inhibiting expression of a target gene comprising using the nucleic acid molecule according to .10. The method for inhibiting expression according to comprising a step of administering the nucleic acid molecule to a cell claim 9 , tissue or organ.11. The method for inhibiting expression according to claim 9 , wherein the nucleic acid molecule is administered in vivo or in vitro.12. The method for inhibiting expression according to claim 9 , wherein the nucleic acid molecule is administered to a non- ...

SURFACES HAVING REDUCED NON-SPECIFIC BINDING AND ANTIGENICITY

Disclosed herein are compositions and methods for reducing the antigenicity of molecules. The antigenicity of a molecule may be reduced or eliminated by conjugating at least one branched polymer to the molecule to form a molecule-polymer conjugate. The branched polymer may include a backbone and a plurality of side chains, each side chain covalently attached to the backbone. 1. A surface having reduced antigenicity and non-specific binding comprising: a surface comprising a plurality of poly[oligo(ethylene glycol) methyl ether methacrylate (POEGMA) polymers comprising a poly(methyl methacrylate) backbone and a plurality of side chains covalently attached to the backbone , each side chain comprising 1 to 9 ethylene glycol monomers repeated in tandem and terminating with an alkoxy moeity.2. The surface of claim 1 , wherein the surface is not reactive with anti-PEG antibodies in a subject.3. The surface of claim 1 , wherein the surface does not bind proteins claim 1 , lipids claim 1 , or carbohydrates non-specifically.4. The surface of claim 1 , wherein the is non-antigenic and does not induce an immune response.5. The surface of claim 1 , wherein the side chain comprises 1 to 5 ethylene glycol monomers repeated in tandem.6. The surface of claim 1 , wherein the side chain comprises 1 to 3 ethylene glycol monomers repeated in tandem.7. The surface of claim 1 , wherein the side chain comprises 2 to 3 ethylene glycol monomers repeated in tandem.8. The surface of claim 1 , wherein the side chain comprises 2 ethylene glycol monomers repeated in tandem.9. The surface of claim 1 , wherein the side chain comprises 3 ethylene glycol monomers repeated in tandem.10. The surface of claim 1 , wherein the alkoxy is methoxy claim 1 , ethoxy claim 1 , or propoxy.11. The surface of claim 1 , wherein the alkoxy is methoxy.12. The surface of claim 1 , wherein the POEGMA comprises monomers of ethylene glycol methyl ether methacrylate (EG-1-OMe).13. The surface of claim 1 , wherein the ...

NITROGEN INFUSED SPARKLING WINE AND METHODS OF MAKING SAME

A carbon dioxide and nitrogen infused wine product includes wine infused with both carbon dioxide and nitrogen. A ratio of carbon dioxide to nitrogen in said wine can be in a range of 80%CO/20%N-60%CO/40%N. 1. A carbon dioxide and nitrogen infused wine product comprising:wine infused with both carbon dioxide and nitrogen;{'sub': 2', '2', '2', '2, 'wherein a ratio of carbon dioxide to nitrogen in said wine is in a range of 80%CO/20%N-60%CO/40%N.'}2. The carbon dioxide and nitrogen infused wine product of claim 1 , wherein said ratio is in the range of 75%CO/25%N-65%CO/35%N.3. A method of infusing wine with carbon dioxide and nitrogen claim 1 , the method comprising:infusing wine with carbon dioxide in a tank; andinfusing the carbon dioxide infused wine with nitrogen in an individual package.4. The method of claim 3 , wherein the step of infusing the wine with carbon dioxide can be performed either by fermentation in the tank or carbonation in the tank.5. The method of claim 4 , wherein the step of infusing the wine with carbon dioxide results in a pressurization of the wine in a range of 15-30 psi.6. The method of claim 5 , wherein the step of infusing the wine with nitrogen in the individual package can be performed using a nitrogen dosing system as part of a bottling or canning process.7. The method of claim 6 , wherein the step of infusing the carbon dioxide infused wine in the individual package can result in the carbon dioxide and nitrogen infused wine in the individual package having a pressure in the range of 35-50 psi.8. The method of claim 7 , wherein a ratio of carbon dioxide to nitrogen in said wine is in a range of 80%CO/20%N-60%CO/40%N.9. The method of claim 8 , wherein said ratio is in the range of 75%CO/25%N-65%CO/35%N.10. A wine product made by the process of:infusing wine with carbon dioxide in a tank; andinfusing the carbon dioxide infused wine with nitrogen in an individual package.11. The wine product of claim 10 , wherein the step of infusing the ...

COMPOUNDS COMPRISING STAPLED OR STITCHED PEPTIDES FOR IMPROVED DRUG DELIVERY

The invention relates to improvements in drug delivery and to the use of Cell Penetrating Agents (CPA's) or Cell Penetrating Peptides (CPP's) which have been stabilized by, for example: i) stapling two amino acids to form Stapled CPP's (StaP's) or ii) stitching three or more amino acids to form stitched CPP's (StiP's). More particularly there is provided a drug carrying cell penetrating molecule (DCCPM) comprising: a biologically active compound (BAC), and a cell penetrating agent (CPA), which BAC and CPA are linked directly or via a bi-functional linker (BFL). The CPA is a stabilized peptide (CPP) which has a conformation imposed upon it by stapling to form a stapled peptide (StaP) or stitching to form a stitched peptide (StiP). The StiP or StaP comprise a cross link or bridge between at least two amino acids of the peptide and the cross link or bridge provides a cyclisation between at least two amino acids which are not formed by an olefin metathesis. Cyclisation may be achieved by one or more of: condensation of an aldehyde or ketone with a hydrazine or protected hydrazine; a thiol-ene Michael addition; a di-sulfide formation; a Huisgen 1,3 di-polar cycloaddition; a reaction between an amine and carboxylic acid; a singlet or triplet based carbine reaction; or a Suzuki or Sonogashira coupling.

RNAI THERAPY FOR HEPATITIS B VIRUS INFECTION

Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hepatitis B virus gene are described. Pharmaceutical compositions comprising one or more HBV RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi triggers to infected liver in vivo provides for inhibition of HBV gene expression and treatment. 129-. (canceled)30. A method of making a double-stranded ribonucleic acid molecule , comprising annealing an antisense strand and a sense strand , wherein:the sense strand comprises a nucleobase sequence according to any one of SEQ ID NOS: 103-105 and 110; andthe antisense strand is at least partially complementary to the sense strand.31. The method of claim 30 , comprising synthesizing the sense strand.32. The method of claim 31 , comprising synthesizing the antisense strand.33. The method of claim 30 , wherein the sense strand comprises a nucleotide sequence according to any one of SEQ ID NOS: 415-421 claim 30 , 470-477 claim 30 , and 492.34. The method of claim 30 , wherein the sense strand comprises a structure according to any one of SEQ ID NOS: 415-421 claim 30 , 470-477 claim 30 , and 492.35. The method of claim 30 , wherein the antisense strand comprises nucleobases 2-18 of any one of SEQ ID NO: 1-4.36. The method of claim 30 , wherein the antisense strand comprises a nucleobase sequence according to any one of SEQ ID NO: 1-4.37. The method of claim 30 , wherein the antisense strand comprises nucleotides 2-18 of any one of SEQ ID NOS: 210-212 claim 30 , 222 claim 30 , 230-247 claim 30 , and 260-262.38. The method of claim 30 , wherein the antisense strand comprises a structure according to any one of SEQ ID NOS: 210-212 claim 30 , 222 claim 30 , 230-247 claim 30 , and 260-262.39. The method of claim 30 , wherein the sense strand is covalently linked to a cholesteryl ...

OLIGOMERS

Certain disclosed oligomers induce exon skipping during processing of myostatin pre-mRNA. The oligomers may be in a vector or encoded by the vector. The vector is used for inducing exon skipping during processing of myostatin pre-mRNA. A therapeutically effective amount of the oligomer may be administered to a subject patient such that exon skipping during processing of myostatin pre-mRNA is induced. The administration to a subject may be used in order to increase or maintain muscle mass, or slowing degeneration of muscle mass in the subject. The administration to a subject may ameliorate muscle wasting conditions, such as muscular dystrophy. Examples of such muscular dystrophies which may be so treated include Becker's muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy, myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy. 2. The oligomer of claim 1 , wherein the oligomer causes an exon skipping rate of at least 40%.3. The oligomer of claim 1 , wherein the oligomer causes an exon skipping rate of at least 90%.4. (canceled)5. The oligomer of claim 1 , wherein the oligomer is a phosphorodiamidate morpholino oligonucleotide (PMO).6. The oligomer of claim 1 , wherein the oligomer is between 20 and 40 bases in length.7. The oligomer of claim 1 , wherein the oligomer is about 30 bases in length.8. The oligomer of claim 1 , wherein the base sequence is selected from SEQ ID NOS. 4 claim 1 , 17 claim 1 , and 18.911.-. (canceled)12. The oligomer of claim 1 , wherein the oligomer is conjugated to or complexed with a distinct chemical entity.13. A vector for inducing exon skipping during processing of myostatin pre-mRNA claim 1 , the vector encoding an oligomer of claim 1 , wherein when the vector is introduced into a cell claim 1 , the oligomer is expressed.14. A method of inducing exon skipping ...

Composition used for contrast imaging

There is provided a composition used for contrast imaging, the composition containing an aqueous solution containing a J-aggregate of indocyanine green and at least one storage stabilizer selected from the group consisting of alkali metal ions, alkaline earth metal ions, and an ammonium ion.

FUSION PROTEIN OF ANTIBODY THAT RECOGNIZES CANCER CELLS AND MUTANT STREPTAVIDIN

It is an object of the present invention to provide a fusion protein of an antibody that recognizes cancer cells and a mutant streptavidin, which is for use in the treatment or diagnosis of cancer. According to the present invention, provided is a fusion protein having the amino acid sequence as set forth in SEQ ID NO: 2 or SEQ ID NO: 7, a linker sequence, and the amino acid sequence as set forth in SEQ ID NO: 1 (provided that the amino acid sequence portion consisting of 6 histidine residues at the C-terminus thereof may be partially or entirely deleted), from the N-terminal side to the C-terminal side, in this order. 1. A fusion protein having the amino acid sequence as set forth in SEQ ID NO: 2 or SEQ ID NO: 7 , a linker sequence , and the amino acid sequence as set forth in SEQ ID NO: 1 (provided that the amino acid sequence portion consisting of 6 histidine residues at the C-terminus thereof may be partially or entirely deleted) , from the N-terminal side to the C-terminal side , in this order.2. The fusion protein according to claim 1 , wherein the number of amino acids of the linker sequence is 5 to 15.3. The fusion protein according to claim 1 , wherein the linker sequence consists of 4 to 14 glycine residues and 1 cysteine residue.4. The fusion protein according to claim 1 , wherein the linker sequence is Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly or Gly-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Gly.5. A fusion protein having the amino acid sequence as set forth in SEQ ID NO: 3 or SEQ ID NO: 8 (provided that the amino acid sequence portion consisting of 6 histidine residues at the C-terminus thereof may be partially or entirely deleted).6. The fusion protein according to claim 1 , further having a secretory signal sequence.7. A fusion protein having the amino acid sequence as set forth in SEQ ID NO: 4 or SEQ ID NO: 9 (provided that the amino acid sequence portion consisting of 6 histidine residues at the C-terminus thereof may be partially or entirely deleted).8. A ...

METHOD OF AND PRESS FOR SEPARATING COCOA MASS INTO COCOA BUTTER AND COCOA CAKE

The invention relates to a method of separating cocoa mass into cocoa butter and cocoa cake by means of a press () comprising one or more pressing elements () in turn comprising a pot () having a cavity () for receiving cocoa mass to be pressed, a squeezer () located at least partially in the cavity (), and at least one filter () disposed in front of the squeezer () and/or on the side of the cavity () opposite the squeezer (), which method comprises the steps of filling the cavity or cavities () with cocoa mass, exerting pressure on the pressing element(s) () thus pressing cocoa butter through the filter(s) (), releasing pressure from the pressing element(s) (), and opening the pot(s) () to remove the cocoa cake(s) from the cavity or cavities (). Prior to releasing the pressure from the pressing element(s) (), cocoa butter is purged from at least the space(s) () behind the filter(s) (). 1. A method of separating cacao mass or products comparable to cacao mass into liquid fat and cake , by means of a press comprising one or more pressing elements , each said pressing element , in turn comprising a pot having a cavity for receiving mass to be pressed , a squeezer located at least partially in the cavity , and at least one filter disposed in front of the squeezer and/or on a side of the cavity opposite the squeezer , which method comprises steps offilling the one or more cavities with mass,exerting pressure on the one or more pressing elements thus pressing liquid fat through the one or more filters,releasing pressure from the one or more pressing elements, andopening the one or more pots to remove one or more cakes from the one or more cavities,characterised in that,prior to the step of releasing the pressure from the one or more pressing elements, liquid fat is purged from at least one or more spaces space(s) behind the one or more filters.2. The method according to claim 1 , wherein claim 1 , prior to the step of releasing the pressure from the one or more pressing ...

Covalent Linkers in Antibody-Drug Conjugates and Methods of Making and Using the Same

The present invention provides novel and advantageous compositions having a linker capable of covalently coupling one or more free thiols of an antibody. Specifically, provided herein are the molecular structures, synthetic pathways, coupling mechanisms, and applications thereof as used in an antibody-drug conjugate (ADC). 172-. (canceled)75. The linker-active agent as claimed in claim 73 , wherein Land Lare independently selected from C-Calkyls claim 73 , C-Calkenyls claim 73 , C-Calkynyls claim 73 , aromatics claim 73 , heteroaryls claim 73 , C-Ccycloalkyls claim 73 , C-Cheterocyclyl claim 73 , polyethylene glycol claim 73 , O claim 73 , S claim 73 , NR claim 73 , C(═O) claim 73 , C(═O)O claim 73 , C(═O)NR claim 73 , C═NR claim 73 , C(═S)O claim 73 , C(═S)NR claim 73 , C(═S)S claim 73 , NR(C═O) claim 73 , NR(C═S)NR claim 73 , O(C═O)NR claim 73 , S(═O) claim 73 , and combinations thereof claim 73 , and wherein Rand Rare independently selected from H claim 73 , C-Calkyls claim 73 , C-Calkenyls claim 73 , and C-Calkynyls; and wherein at least one L comprises a C-Calkyl claim 73 , C-Calkenyl claim 73 , C-Calkynl claim 73 , aromatic claim 73 , heteroaryl claim 73 , C-Ccycloalkyl claim 73 , C-Cheterocyclyl claim 73 , polyethylene glycol claim 73 , O claim 73 , S claim 73 , NR claim 73 , C(═O) claim 73 , C(═O)O claim 73 , C(═O)NR claim 73 , C═NR claim 73 , C(═S)O claim 73 , C(═S)NR claim 73 , C(═S)S claim 73 , NR(C═O) claim 73 , NR(C═S)NR claim 73 , O(C═O)NR claim 73 , S(═O) claim 73 , Val-Cit-PAB claim 73 , Val-Ala-PAB claim 73 , Val-Lys(Ac)-PAB claim 73 , Phe-Lys-PAB claim 73 , Phe-Lys(Ac)-PAB claim 73 , D-Val-Leu-Lys claim 73 , Gly-Gly-Arg claim 73 , Ala-Ala-Asn-PAB claim 73 , Ala-PAB claim 73 , PAB claim 73 , or a combination thereof claim 73 , and wherein Rand Rare independently selected from H claim 73 , C-Calkyls claim 73 , C-Calkenyls claim 73 , and C-Calkynyls.76. The linker-active agent as claimed in claim 73 , wherein said Q is selected from tubulin binders ...

Nanoparticles for controlled lysis of blood clots

Fibrinolytic nanoparticles including a polymeric core having a surface that is functionalized with a cationic amphiphilic compound, and a fibrinolytic agent dispersed within the core, are described herein. The fibrinolytic nanoparticles can be used in method of dissolving a blood clot in a subject by administering to the subject a therapeutically effective amount of fibrinolytic nanoparticles.

PH-RESPONSIVE POLYMER AND DRUG DELIVERY SYSTEM

A pH-responsive polymer formed of a biocompatible polymer to which a group which is electrically neutral under pH environments of more than 7 and which changes to be cationic at pH 7 or less is bonded. 1. A pH-responsive polymer , comprising:a biocompatible polymer to which a group which is electrically neutral under pH environments of more than 7 and which changes to be cationic at pH 7 or less is bonded.2. The pH-responsive polymer according to claim 1 ,wherein the group which is electrically neutral under pH environments of more than 7 and which changes to be cationic at pH 7 or less is a group which is electrically neutral under pH environments of 7.2 to 7.6 and which changes to be cationic under pH environments of 6.0 to 6.6.4. The pH-responsive polymer according to claim 1 ,wherein the group which is electrically neutral under pH environments of more than 7 and which changes to be cationic at pH 7 or less includes a carboxyl group, a sulfo group, or a phosphonic group.6. The pH-responsive polymer according to claim 1 ,wherein the biocompatible polymer is biodegradable.7. The pH-responsive polymer according to claim 6 ,wherein the biocompatible polymer is selected from the group consisting of polyamino acids, polyesters, polynucleotides, and polysaccharides.8. The pH-responsive polymer according to claim 7 ,wherein the biocompatible polymer is a polyamino acid.9. The pH-responsive polymer according to claim 8 ,wherein the polyamino acid is polyglutamic acid or polyaspartic acid.12. The pH-responsive polymer according to claim 1 ,wherein a weight-average molecular weight is 1,000 to 200,000.13. The pH-responsive polymer according to claim 12 ,wherein a weight-average molecular weight is 10,000 to 50,000.14. The pH-responsive polymer according to claim 1 ,wherein 4 to 800 mol of the group which is electrically neutral under pH environments of more than 7 and which changes to be cationic at pH 7 or less is bonded per one mol of the biocompatible polymer.15. The pH ...

Self-assembly of therapeutic agent-peptide nanostructures

Disclosed are conjugates of hydrophobic drugs linked to protected or unprotected amino acids or peptides. The disclosed conjugates are amphiphilic and can self assemble into nanotubes. Nanotubes comprising the conjugates are also described and can have high loading of the drug and protect it from degradation or elimination. The nanotubes are well suited to deliver hydrophobic and unstable drugs to individuals.

ACYLATED GLUCAGON ANALOGUES

The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon. 230.-. (canceled)34. A compound according to wherein Z has the formula:{'br': None, 'H-Aib-QGTFTSDYSKYLDS-K(Hexadecanoyl-isoGlu)-AAHDFVEWLLS\u2003\u2003(SEQ ID NO:121);'}{'br': None, 'H-Aib-QGTFTSDYSKYLDS-K(Hexadecanoyl-isoGlu)-AAHDFVEWLL\u2003\u2003(SEQ ID NO:122);'}or a pharmaceutically acceptable salt thereof.36. A compound according to wherein Z has the formula:{'br': None, 'H-Aib-EGTFTSDYSKYLDS-K(Hexadecanoyl-isoGlu)-AAHDFVEWLLSA\u2003\u2003(SEQ ID NO: 123);'}or a pharmaceutically acceptable salt thereof.37. A composition comprising a compound claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , in a mixture with a carrier.3839.-. (canceled)40. A method of diminishing weight gain or promoting weight loss in a subject claim 1 , by administering a compound of to said subject claim 1 , in an amount sufficient to diminish weight gain or promote weight loss.41. A method of improving circulating glucose levels claim 1 , glucose tolerance and/or circulating cholesterol levels claim 1 , lowering circulating LDL levels claim 1 , and/or increasing HDL/LDL ratio in a subject claim 1 , by administering a compound of to said subject claim 1 , in an amount sufficient to improve circulating glucose levels claim 1 , glucose tolerance and/or circulating cholesterol levels claim 1 , lowering circulating LDL levels claim 1 , and/or increasing HDL/LDL ratio.42. A method of treatment of a condition caused or characterized by excess body weight claim 1 , and the treatment of obesity claim 1 , morbid obesity claim 1 , obesity linked inflammation claim 1 , obesity linked ...

POLYHYDROXYLATED BILE ACIDS FOR TREATMENT OF BILIARY DISORDERS

The invention provides, in part, polyhydroxylated bile adds for treating biliary disorders, for example, biliary disorders arising out of cholestasis of portal hypertension. The invention also provides, in part, polyhydroxylated bile acids for stimulating bile flow. New compounds 2α,3α,7α,12α-tetrahydroxy-5β-cholanoic acid and 3α,4α,7α,12α-tetrahydroxy-5β-cholanoic acid are disclosed, uses thereof and synthesis thereof. 2. The method of wherein said compound is selected from the group consisting of a tetrahydroxylated bile acid and a pentahydroxylated bile acid claim 1 , or a derivative thereof.3. The method of wherein said tetrahydroxylated bile acid is selected from the group consisting of:a 3,6,7,12-tetrahydroxycholanoic acid,a 3,4,7,12-tetrahydroxycholanoic acid,a 1,3,7,12-tetrahydroxycholanoic acid,a 2,3,7,12-tetrahydroxycholanoic acid,a 3,7,16,24-tetrahydroxycholanoic acid, anda 3,7,15,24-tetrahydroxycholanoic acid,or a derivative thereof.4. The method of wherein said 3 claim 3 ,6 claim 3 ,7 claim 3 ,12-tetrahydroxycholanoic acid is selected from the group consisting of:a 3α,6α,7α,12α-tetrahydroxy-5β-cholan-24-oic acid,a 3α,6β,7α,12α-tetrahydroxy-5β-cholan-24-oic acid,a 3α,6α,7β,12α-tetrahydroxy-5β-cholan-24-oic acid,a 3α,6β,7β,12α-tetrahydroxy-5β-cholan-24-oic acid,a 3α,6α,7α,12β-tetrahydroxy-5β-cholan-24-oic acid,a 3α,6β,7α,12β-tetrahydroxy-5β-cholan-24-oic acid, anda 3α,6β,7β,12β-tetrahydroxy-5β-cholan-24-oic acid,or wherein said 2,3,7,12-tetrahydroxycholanic acid is a 2α,3α,7α,12α-tetrahydroxy-5β-cholanic acid,or wherein said a 3,4,7,12-tetrahydroxycholanic acid is a 3α,4α,7α,12α-tetrahydroxy-5β-cholanic acid,or a derivative thereof.5. The method of wherein said compound has a hydrophilicity greater than that of cholate claim 1 , or has a preferential affinity for MDRI when compared to BSEP claim 1 , or wherein said compound has a high affinity for MDR1 claim 1 , or wherein said compound is selected from the group consisting of a tauryl or glycyl conjugate ...

METHODS FOR IMPROVED DELIVERY OF AMINOTHIOLS, DIMERS OF AMINOTHIOLS, AND HETERODIMERS COMPOSED OF AMINOTHIOLS

The disclosure relates to methods of improving safety, efficacy, or both, of pharmaceutically active aminothiol compounds by delivering them in a thiol-protected form and, preferably intracellularly. 1. A method of administering an aminothiol compound to a subject in need of aminothiol therapy , the method comprising administering the aminothiol in a thiol-protected form.2. The method of claim 1 , wherein the thiol-protected form of the aminothiol comprises the aminothiol conjugated with an intracellularly-cleavable thiol protecting group.3. The method of claim 1 , wherein the intracellularly-cleavable protecting group is selected from the group consisting of a peptide claim 1 , a sulfur-containing amino acid claim 1 , glutathione claim 1 , a sulfur-containing antioxidant claim 1 , an oxygen-containing antioxidant claim 1 , a photoreversible thiol tag claim 1 , and (R)-tert-butyl-2-[(tert-butoxycarbonyl)amino]-3-(tryitylsulfanyl)propanoate.4. The method of claim 1 , wherein the thiol-protected form of the aminothiol is selected from the group consisting of a homodimer of the aminothiol claim 1 , a heterodimer of the aminothiol and a different aminothiol claim 1 , and cysteamine.6. The method of claim 1 , wherein the thiol-protected form of the aminothiol is administered in an intracellular delivery system.7. The method of claim 6 , wherein the intracellular delivery system is selected from the group consisting of: (a) systems comprising a cell penetrating agent claim 6 , (b) pH-responsive carriers claim 6 , (c) C2-streptavidin delivery systems claim 6 , (d) CH(3)-TDDS drug delivery systems claim 6 , (e) hydrophobic bioactive carriers claim 6 , (f) exosomes claim 6 , (g) lipid-based delivery systems claim 6 , (h) liposome-based delivery systems claim 6 , (i) micellar delivery systems claim 6 , (j) microparticles claim 6 , (k) molecular carriers claim 6 , (l) nanocarriers claim 6 , (m) nanoscopic multi-variant carriers claim 6 , (n) nanogels claim 6 , (o) hybrid ...

APPARATUS FOR MANUFACTURING COSMETICS, COMPRISING CONTENTS ABSORPTION STEP USING ABSORBENT

The apparatus for manufacturing cosmetics comprises the contents absorption step using an absorbent including: (1) a transfer table for transferring a cosmetic container, (2) a suction portion for sucking foreign matter inside an accommodation space of the cosmetic container, (3) a contents injection portion for injecting contents into the accommodation space, (4) an absorbent supply portion for injecting an absorbent into the accommodation space, (5) an absorbent press portion for repeatedly pressing the absorbent inside the accommodation portion, (6) an edge member supply portion for injecting an edge member for fixing the absorbent inside the accommodation space, and (7) an absorbent fixing portion for allowing the edge member to be fixed inside the accommodation space. 1. A cosmetics manufacturing apparatus comprising a process of absorbing contents by an absorbent , the apparatus comprising:a feeding table by which a cosmetics container is fed;a suction unit for suctioning foreign substances from an accommodation space of the cosmetics container;a contents injection unit for injecting contents into the accommodation space from which the foreign substances are suctioned by the suction unit;an absorbent supply unit for introducing an absorbent into the accommodation space into which the contents are injected by the contents injection unit;an absorbent pressing unit for repeatedly pressing the absorbent and absorbing the contents into the absorbent;a edge member supply unit for introducing a edge member for fixing the absorbent to the accommodation space into the accommodation space; andan absorbent fixing unit for fixing the edge member to the accommodation space while the edge member presses and fixes a circumference of the absorbent.2. The apparatus of claim 1 , wherein the suction unit claim 1 , the contents injection unit claim 1 , the absorbent supply unit claim 1 , the absorbent pressing unit claim 1 , the edge member supply unit claim 1 , and the absorbent ...

POLYETHYLENIMINE (PEI)-POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF

The present application provides PEI compounds comprising a linker, PEI-polypeptide conjugates (e.g., PEI-antibody conjugates), and complexes thereof comprising a biologically active molecule. Methods of preparing and using the compounds, conjugates and complexes are further provided. The PEI-polypeptide conjugates and complexes are useful for delivering biologically active molecules to the cytoplasm of cells and promoting release of the biologically active molecules from the endo-lysosomal pathway. 114-. (canceled)15: A compound of the formula (IV):{'br': None, 'sup': 10', '20, 'sub': 'q', '(PEI-L-)-R\u2003\u2003(IV)'}or a salt thereof, wherein{'sub': '1-6', 'PEI is polyethylenimine, which terminates with —OH or —NHR, wherein R is hydrogen or Calkyl;'}{'sup': '10', 'Lis a linker;'}q is a number from one to 100; and{'sup': '20', 'Ris a polypeptide.'}16: The compound of claim 15 , wherein the linkage between Rand Lis formed via a thiol modification reaction claim 15 , a click reaction claim 15 , or an enzymatic reaction.17: The compound of claim 15 , wherein q is one.18: The compound of claim 15 , wherein Ris a targeting polypeptide.19: The compound of claim 15 , wherein Ris an Fc-containing polypeptide or a Fab-containing polypeptide.20: The compound of claim 19 , wherein Ris an antibody.21: The compound of claim 19 , wherein Rspecifically binds to an intracellular molecule.22: The compound of claim 19 , wherein Rspecifically binds to an extracellular molecule.23: The compound of claim 20 , wherein Ris a multispecific antibody.24: The compound of claim 23 , wherein the multispecific antibody comprises a first binding domain that specifically binds to an extracellular molecule and a second binding domain and specifically binds to an intracellular molecule.25: The compound of claim 15 , wherein Lis —SiRR—(CH) claim 15 , —SiRR—(CH)—NH—C(O)—NH—(CH)— claim 15 , —SiRR—(CH)—C(O)—NH—(CH)— claim 15 , or-SiRR—(CH)—NH—C(O)—(CH)—; wherein Rand Rare independently optionally ...

CONJUGATE WITH TARGET-FINDING LIGAND AND USE THEREOF

Described is a conjugate of agent complex and at least one target-finding ligand, where the agent complex comprises an agent encapsulated by an encapsulation material and where the target-finding ligand is a prostacyclin analog, and the use of the conjugate. 1. A conjugate of agent complex and at least one target-finding ligand , where the agent complex comprises an agent encapsulated with an encapsulation material comprising a lipid , and where the target-finding ligand is a prostacyclin analog.2. The conjugate according to claim 1 , wherein the prostacyclin analog is iloprost or treprostinil.3. The conjugate according to claim 1 , wherein the agent is a nucleic acid or a derivative thereof claim 1 , a peptide claim 1 , polypeptide or derivative thereof claim 1 , an active substance or a tracer.4. The conjugate according to claim 3 , wherein the agent is a nucleic acid claim 3 , and wherein the nucleic acid is a DNA or RNA whose lack or deficiency causes a disease or is a DNA or RNA which encodes a polypeptide whose lack or deficiency causes a disease or which has an immunomodulatory activity.5. The conjugate according to claim 3 , wherein the agent is a peptide or polypeptide whose lack or deficiency causes a disease or which has an immunomodulatory activity.6. The conjugate according to claim 3 , wherein the agent is an active substance claim 3 , and wherein the active substance is an anti-inflammatory active substance or a steroid.7. The conjugate according to claim 3 , wherein the agent is a nucleic acid claim 3 , and wherein the agent complex of encapsulation material and nucleic acid is additionally pegylated.8. The conjugate according to claim 1 , wherein the agent is a product which compensates for a protein defect or lack of protein and is selected from the group consisting of nucleic acid claim 1 , protein claim 1 , protein derivative or protein fragment claim 1 , a pharmaceutical which is active in the lungs claim 1 , or a mixture thereof.9. The ...

PROCESS FOR RECOVERING ORGANICS FROM MATERIAL RECOVERY FACILITY FINES

A system and process for separating organic material from solid waste such as material recovery facility (MRF) fines is disclosed. The fines are treated in a press, in which the fines are compressed against a wall having a set of holes. The fines are mixed with a substantial amount of water before being pressed. The water increases the amount of organic matter that is recovered from the fines. A wet fraction, extruded through the holes of the press, may be treated in an anaerobic digester. 1. A process comprising steps of ,mixing water with solid waste in an amount of at least 50% water by mass per unit mass of solid waste; and,pressing the resulting mixture at a pressure of at least 50 bar in an extrusion chamber.2. The process of further comprising mixing water with the solid waste in an amount of at least 50% water per unit mass of solid waste.3. The method of wherein the solid waste is fines from a material recovery facility.4. The method of wherein the fines pass through a rectangular opening that is 51 mm or less on each side claim 3 , or a round opening of 51 mm or less in diameter.5. The method of where the solid waste comprises at least 25% organic material by dry mass.6. The method of wherein the water and solid waste are mixed for at least 15 minutes.7. The method of wherein one or more walls of the extrusion chamber has holes with an area equal to the area of a circle with a diameter in a range of 4 mm to 20 mm.8. A system for treating solid waste comprising a mixer claim 1 , a supply of water and a high pressure extrusion press.9. The system of wherein the mixer is connected to the supply of water and the press is downstream of the mixer.10. The system of further comprising a material recovery facility adapted to produce fines from solid waste claim 8 , wherein the mixer receives the fines. This specification relates to recovering organic material from waste such as municipal solid waste (MSW).A material recovery facility (MRF) receives waste, such as ...

COMPOUNDS FOR DELIVERING GLUTATHIONE TO A TARGET AND METHODS OF MAKING AND USING THE SAME

Disclosed herein are embodiments of compounds that can be used to target glutathione to various target sites, such as cells, mitochondria, and other organelles. Also disclosed herein are embodiments of methods for making and using the compounds. In particular disclosed embodiments, the compounds can be used to treat, ameliorate, and/or prevent diseases or conditions associated with low or reduced glutathione levels, as well as other types of diseases/conditions. 3. The compound of claim 1 , wherein the protecting group is selected from methyl; ethyl; propyl; butyl; pentyl; hexyl; septyl; octyl; nonyl; decyl; ethyl amine; phenyl; naphthyl; —(CH)Ph claim 1 , wherein m is 1 to 20; fluorenylmethyl; silyl-oxyether having a formula —[(CH)O]—[(CH)]SiR claim 1 , wherein n ranges from 1 to 10 claim 1 , m ranges from 0 to 10 claim 1 , and p ranges from 1 to 10; trihaloalkyl; diaryl; alkyldiaryl; or an ester thereof.7. The compound of claim 6 , wherein each Rand Rindependently is alkyl selected from methyl or ethyl. 108. The compound of claim 6 , wherein each linker independently is —C(O)R— wherein Ris aliphatic.13. A pharmaceutical composition claim 6 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a compound according to ; and'}a pharmaceutically acceptable carrier.14. The pharmaceutical composition of claim 13 , wherein the composition further comprises one or more additional therapeutic agents selected from N-acetyl cysteine claim 13 , vitamin E claim 13 , vitamin C claim 13 , and diacetyl-bis(4-methylthiosemicarbazonato)copperII.15. A method claim 1 , comprising administering to a subject a therapeutically effective amount of a compound according to claim 1 , and/or a pharmaceutical composition thereof.16. The method of claim 15 , wherein the compound and/or pharmaceutical compositions is used to treat claim 15 , ameliorate claim 15 , and/or prevent a disease or condition associated with low or reduced glutathione levels.17. The method of claim 15 , ...

Additive for carbonated beverage

The present invention relates to a thirst-quenching carbonated beverage with a strengthened or sustained carbonation feel peculiar to known carbonated beverages in which, after opening, the carbonation feel rapidly drops depending upon a combination of raw materials employed and upon evaporation of the carbon dioxide gas. The present invention also relates to a method which includes adding to a carbonated beverage an additive comprising spilanthol or a spilanthol-containing plant extract or plant essential oil as an active ingredient.

TARGETING MITOCHONDRIAL FISSION THROUGH MDIVI-1 DERIVATIVES

Derivatives of mDIVI-1 may be used to target and eliminate cancer stem cells. Disruption in the mitochondrial dynamics balance plays a role in cancer. Proteins involved in regulating mitochondrial dynamics represent potential targets for cancer treatment. Mitochondrial fission protein DRP1 is such a target. Derivatives of mDIVI-1 inhibit DRP1, and have demonstrated inhibition of tumorsphere forming capacity, migration and stemness-related signaling in breast cancer cells. These properties result from induction of mitochondrial oxidative stress and reduction of mitochondrial metabolism in the target cancer cells. The potency of an mDIVI-1 derivative may be dramatically increased through addition of at least one membrane-targeting signal and/or a mitochondria-targeting signal. 2. The mDIVI-1 derivative of claim 1 , wherein at least one R-group comprises a targeting signal selected from the group consisting of palmitic acid claim 1 , stearic acid claim 1 , myristic acid claim 1 , and oleic acid claim 1 , a short-chain fatty acid claim 1 , a medium-chain fatty acid claim 1 , tri-phenyl-phosphonium (TPP) claim 1 , a TPP-derivative claim 1 , a lipophilic cation claim 1 , and 10-N-nonyl acridine orange.3. The mDIVI-1 derivative of claim 1 , wherein at least one R-group is a mitochondria-targeting signal that comprises at least one of 2-butene-1 claim 1 ,4-bis-TPP; 2-chlorobenzyl-TPP; 3-methylbenzyl-TPP; 2 claim 1 ,4-dichlorobenzyl-TPP; 1-naphthylmethyl-TPP; p-xylylenebis-TPP; a derivative of 2-butene-1 claim 1 ,4-bis-TPP; a derivative of 2-chlorobenzyl-TPP; a derivative of 3-methylbenzyl-TPP; a derivative of 2 claim 1 ,4-dichlorobenzyl-TPP; a derivative of 1-naphthylmethyl-TPP; and a derivative of p-xylylenebis-TPP.4. The mDIVI-1 derivative of any of - claim 1 , wherein the mDIVI-1 derivative possesses at least one of anti-aging activity claim 1 , radiosensitizing activity claim 1 , photosensitizing activity claim 1 , and anti-microbial activity.5. The mDIVI-1 derivative ...

MODIFIED ANTIBODIES AND RELATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE

Provided herein are modified antibodies, compounds used to make them, and intermediates in their synthesis; corn positions; formulations and methods, including methods of treating diseases, disorders or conditions, for example, cancer, in humans. 5. The method of claim 1 , wherein the bond represents a single bond.6. The method of claim 1 , wherein each Y and Y′ is independently selected from the group consisting of a halo claim 1 , a substituted thiol claim 1 , and a substituted sulfonate.7. The method of claim 1 , wherein each Y and Y′ is independently selected from the group consisting of chloro claim 1 , bromo claim 1 , fluoro claim 1 , and iodo.8. The method of claim 1 , wherein each Y and Y′ is independently selected from an optionally substituted thiophenyl claim 1 , an optionally substituted thionaphthyl claim 1 , an optionally substitued thiopyridyl claim 1 , an optionally substituted isoquinolinyl claim 1 , and an optionally substituted phenylsulfonate.15. The modified antibody of claim 11 , wherein the bond represents a single bond.16. The modified antibody of claim 11 , wherein n is 4.17. The modified antibody of claim 11 , wherein A is an antibody that is specific to a cancer antigen.18. The modified antibody of claim 11 , wherein A is selected from the group consisting of alemtuzumab claim 11 , anitumumab claim 11 , bevacizumab claim 11 , brentuximab claim 11 , cetuximab claim 11 , gemtuzumab claim 11 , glembatumumab claim 11 , inotuzumab claim 11 , ipilimumab claim 11 , lovortumumab claim 11 , milatuzumab claim 11 , ofatumumab claim 11 , rituximab claim 11 , tositumomab claim 11 , and trastuzumab.19. A modified antibody or a formulation thereof obtainable by the method of .20. A process claim 1 , which comprises:(i) reducing one or more interchain cysteine-cysteine disulfide bonds in an antibody with a reducing agent; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(ii) reacting the free thiol groups from the one or more reduced interchain ...

Halogenated Phenols for Diagnostics, Antioxidant Protection and Drug Delivery

The present invention provides compositions and methods for the targeted delivery, release and/or formation of a drug compound at a target site(s) within the body of an individual, such as a diseased and/or inflamed tissue in the body of the individual. These compositions may comprise a halogenated phenol ring cleavably linked to a core structure of a drug compound. Due to the variety of substituents that may be utilized in forming the different types of linkages, numerous examples of drug compounds linked to a halogenated phenol ring are proposed. The present invention further provides compositions comprising halogenated phenol starting compounds that do not undergo cleavage during a dehalogenation reaction to form a drug compound in a targeted tissue when administered to an individual. Methods of administering these non-cleaving compounds are further provided. 2. The compound of claim 1 ,wherein the steroid is a corticosteroid.3. The compound of claim 1 ,wherein Y is bonded to a carbon of a carbon ring of the corticosteroid.4. The compound of claim 2 ,wherein the corticosteroid is cortisone.5. The compound of claim 2 ,wherein the corticosteroid is cortisol.6. The compound of claim 2 ,wherein the corticosteroid is corticosterone.7. The compound of claim 2 ,wherein the corticosteroid is hydrocortisone.8. The compound of claim 2 ,wherein the corticosteroid is prednisone.9. The compound of claim 2 ,wherein the corticosteroid is prednisolone.10. The compound of claim 2 ,wherein the corticosteroid is methylprednisolone.11. The compound of claim 2 ,wherein the corticosteroid is betamethasone.12. The compound of claim 2 ,wherein the corticosteroid is dexamethasone.13. The compound of claim 1 ,wherein the steroid is estrogen.15. The compound of claim 1 , wherein R claim 1 , R claim 1 , and Rare each a hydrogen.16. The compound of claim 1 , wherein the ether linkage (—Y—) is para to the halogen (X).17. The compound of claim 1 , wherein the ether linkage (—Y—) is ortho to ...

Packaging Assemblies for Product Components, and Related Methods

A packaging assembly is provided for holding multiple different product components, where the different product components are usable together to form a product. The packaging assembly includes a base and at least one sidewall coupled to the base. A first compartment is disposed generally above the base and is configured to hold a first component. A second compartment is disposed generally above the first compartment and is configured to hold a second component. The packaging assembly also includes a divider positioned between the first and second compartments, a lid disposed generally over the second compartment, at least one securing device configured to secure the lid to the at least one sidewall, and at least one cross member disposed generally above the lid which is coupled to the at least one sidewall. 1. A packaging assembly for two or more different product components , the packaging assembly comprising:a base;at least one sidewall coupled to the base;a first compartment disposed adjacent the base and configured to hold at least a first component;a second compartment disposed adjacent the first compartment, the second compartment configured to hold at least a second component;a divider positioned between the first and second compartments;at least one internal cross member coupled to the at least one sidewall, the at least one internal cross member configured to support the divider;a lid disposed generally over the second compartment; andat least one securing device configured to secure the lid to the at least one sidewall.2. The packaging assembly of claim 1 , further comprising:at least one first container positioned within the first compartment, the at least one first container configured to hold at least the first component; andat least one second container positioned within the second compartment, the at least one second container configured to hold at least the second component.3. The packaging assembly of claim 2 , wherein the at least one first ...

TRANSFECTION REAGENTS FOR DELIVERY OF NUCLEIC ACIDS

Polymeric transfection reagents for delivery of nucleic acids to cells, pharmaceutical compositions comprising same, and methods of preparing and using same are provided. A compound comprises polyethylenimine, a lipid selected from cholesterol, lauric acid, palmitic acid, or stearic acid, and optionally, a histidine. A nanoparticle comprises the compound complexed to a nucleic acid. A composition or pharmaceutical composition comprises the nanoparticle and a pharmaceutically acceptable carrier, anti-fouling agent, targeting ligand, or combinations thereof. A method of treating, preventing, or ameliorating a disease in a subject comprises administering to the subject an effective amount of the nanoparticle or the composition or pharmaceutical composition. 1. A compound comprising a polymer and a lipid covalently linked via N-acylation , the polymer is polyethylenimine having a molecular weight ranging from 0.6 kDa to 2.0 kDa , and the lipid is cholesterol or a derivative thereof , or lauric acid.2. The compound of claim 1 , wherein the polymer is polyethylenimine in a branched or linear form.3. The compound of claim 1 , wherein the derivative of cholesterol is cholic acid or deoxycholic acid.4. The compound of claim 2 , wherein the polymer is polyethylenimine in a branched or linear form and is coupled to histidine and cholesterol or a derivative thereof.7. The compound of claim 6 , wherein the chemical group is selected from disulfide claim 6 , thioester claim 6 , ester claim 6 , orthoester claim 6 , anhydride claim 6 , a phosphoester claim 6 , acetal claim 6 , ketal claim 6 , or carbonate.10. A nanoparticle comprising the compound of complexed to a nucleic acid.11. The nanoparticle of claim 10 , wherein the nucleic acid is selected from siRNA claim 10 , microRNA claim 10 , a DNA-based oligonucleotide or antisense oligonucleotide claim 10 , a peptide-nucleic acid claim 10 , DNA-RNA chimeras claim 10 , messenger RNA claim 10 , or combinations thereof.1214-. (canceled ...

METHOD FOR CREATION AND DISTRIBUTION OF A TEA FLAVORED ALCOHOLIC BEVERAGE

The invention is a refreshing drink that is tea flavored and also has alcohol in it. It comprises a tea extract, lemon juice, citric acid, and sec champagne combination that are within well defined concentration thresholds for the creation of the beverage. Further it is contemplated that a unique method of preparation is fun for the consumers and creators of the beverage which will enhance the social aspects of its consumption. 1. A method for creating a beverage comprising;procuring tea extract, champagne, water, sugar and citric acidmixing said tea extract, said champagne, said water, said sugar and said citric acid into a containerwherein the champagne concentration is diluted by half by said water.2. The method of wherein said champagne is a sweet sec champagne.3. The method of wherein said champagne is a rose champagne.4. The method of wherein said rose champagne is a sweet sec champagne.5. The method of wherein said citric acid is a component of lemon juice.6. The method of wherein said tea extract is concentrated soluble tea.7. The method of wherein said tea extract is either oolong claim 5 , green or black tea powder mix.8. The method of where said tea extract is iced tea mix.9. The method of wherein said champagne is at a concentration between 50-55% of the initial 100% champagne concentration after dilution with said water.10. The method of wherein said champagne is at a concentration between 55-60% of the initial 100% champagne concentration after dilution with said water.11. The method of wherein said iced tea mix is present at a final concentration between 8-12% of the final beverage volume.12. The method of wherein said tea extract is present at a final concentration between 3-4% of the final beverage volume.13. The method of wherein said citric acid is present at a final concentration between 0.01 to 0.005%.14. The method of wherein said citric acid is present at a final concentration between 0.01 to 0.005%.15. A method for creating a beverage ...

Mitochondrial Targeted Releasable Linker

There is described herein compound comprising a mitochondrial targeting portion, a cargo portion including a drug unit, and a linker conjugating the mitochondrial targeting portion and the cargo portion, the linker portion cleavable in a mitochondrion of a cell for preferentially releasing the cargo portion within the mitochondrion as compared to a cytoplasm of the cell. 1. A compound comprising:a mitochondrial targeting portion;a cargo portion including a drug unit; anda linker conjugating the mitochondrial targeting portion and the cargo portion, the linker portion cleavable in a mitochondrion of a cell for preferentially releasing the cargo portion within the mitochondrion as compared to a cytoplasm of the cell.2. The compound of claim 1 , wherein the linker portion comprises disulfide.3. The compound of claim 2 , wherein each carbon atom bonded to the disulfide is claim 2 , independently claim 2 , unsubstituted; mono- or di-substituted by claim 2 , independently claim 2 , a hydroxyl claim 2 , amino claim 2 , fluoro claim 2 , chloro claim 2 , bromo claim 2 , C-Calkyl claim 2 , C-Calkenyl claim 2 , C-Calkynyl claim 2 , C-Ccycloalkyl claim 2 , C-Ccycloalkenyl claim 2 , or phenyl group; or di-substituted such that the carbon atom bonded to the disulfide forms part of a C-Ccycloalkyl claim 2 , or C-Ccycloalkenyl.4. The compound of claim 1 , wherein the drug unit includes a hydroxyl claim 1 , amine or thiol group.5. The compound of claim 1 , wherein the cargo portion includes an auto-cyclization moiety that activates by the cleavage of the linker to release the drug unit.6. The compound of claim 5 , wherein the auto-cyclization moiety includes an ester moiety that reacts with a moiety of the cleaved linker portion.7. The compound of claim 6 , wherein the moiety of the cleaved linker portion that reacts with the ester moiety is a sulfur moiety.8. The compound of claim 6 , wherein the drug unit includes an oxygen moiety bonded to the ester moiety to form a carbonate ...

METHODS FOR IMPROVED DELIVERY OF AMINOTHIOLS, DIMERS OF AMINOTHIOLS, AND HETERODIMERS COMPOSED OF AMINOTHIOLS

The disclosure relates to methods of improving safety, efficacy, or both, of pharmaceutically active aminothiol compounds by delivering them in a thiol-protected form and, preferably intracellularly. 1. A method of administering an aminothiol compound to a subject in need of aminothiol therapy , the method comprising administering the aminothiol in a thiol-protected form.2. The method of claim 1 , wherein the thiol-protected form of the aminothiol comprises the aminothiol conjugated with an intracellularly-cleavable thiol protecting group.3. The method of claim 1 , wherein the intracellularly-cleavable protecting group is selected from the group consisting of a peptide claim 1 , a sulfur-containing amino acid claim 1 , glutathione claim 1 , a sulfur-containing antioxidant claim 1 , an oxygen-containing antioxidant claim 1 , a photoreversible thiol tag claim 1 , and (R)-tert-butyl-2-[(tert-butoxycarbonyl)amino]-3-(tryitylsulfanyl)propanoate.4. The method of claim 1 , wherein the thiol-protected form of the aminothiol is selected from the group consisting of a homodimer of the aminothiol claim 1 , a heterodimer of the aminothiol and a different aminothiol claim 1 , and cysteamine.6. The method of claim 1 , wherein the thiol-protected form of the aminothiol is administered in an intracellular delivery system.7. The method of claim 6 , wherein the intracellular delivery system is selected from the group consisting of: (a) systems comprising a cell penetrating agent claim 6 , (b) pH-responsive carriers claim 6 , (c) C2-streptavidin delivery systems claim 6 , (d) CH(3)-TDDS drug delivery systems claim 6 , (e) hydrophobic bioactive carriers claim 6 , (f) exosomes claim 6 , (g) lipid-based delivery systems claim 6 , (h) Liposome-based delivery systems claim 6 , (i) micellar delivery systems claim 6 , (j) microparticles claim 6 , (k) molecular carriers claim 6 , (l) nanocarriers claim 6 , (m) nanoscopic multi-variant carriers claim 6 , (n) nanogels claim 6 , (o) hybrid ...

FULLERENE GABA DOPA AND METHODS

A novel dual neurotransmitter nanoparticle composition is provided to store and transport protons and cations into neural cell membranes and to disassemble salt-bridge stabilized toxic protein plaques. These properties function to mitigate cognitive deficits in neurological diseases such as Parkinson's disease and Alzheimer's disease, as well as to reduce the severity of Inflammatory Bowel Syndrome, and aging related reactive oxygen species damage by promoting the sequestration and termination of free radicals and reactive oxygen species. The composition comprises C60 bonded to one or more gamma amino butyric acid molecules and one or more molecules of either levodopa or dopamine. The composition can be produced at low temperatures through reactive shear milling. This composition therapeutically improves and prophylactically preserves cognitive performance, memory, and mental acuity on aging to promote mental performance and health-span improvement. 1. A compound comprising:a buckminsterfullerene C60 bonded to a first neurotransmitter of the presynaptic terminal, and bonded to a second neurotransmitter of the postsynaptic terminal.2. The compound of wherein the first neurotransmitter comprises GABA and the second neurotransmitter comprises either levodopa or dopamine.3. The compound of further comprising a second and a third GABA and a second L-dopa all bonded to the buckminsterfullerene C60.4. The compound of wherein the buckminsterfullerene C60 bonded to the first and second neurotransmitters is disposed within a zeolite.5. A method of curing claim 1 , treating claim 1 , or prophylactically avoiding motor neuron dysfunction related to oligomeric alpha-synuclein plaque formation in Parkinson's disease claim 1 , Lewy Body Disease claim 1 , or Inflammatory Bowel Disease in a subject claim 1 , or prophylactically avoiding motor neuron dysfunction related to oligomeric plaque formation in Alzheimer's disease or Amyotrophic Lateral Sclerosis (ALS) in the subject claim 1 ...

Supramolecular protein assemblies with advanced functions and synthesis thereof

The present invention discloses stimuli-sensitive protein conjugate which can make supramolecular protein assemblies and methods for using the same. The present invention provides simple and rational process for construction of said stimuli-sensitive spherical protein assemblies through supramolecular chemical strategy.

FULLERENE PHOSPHONATE GALLOYLS AND METHODS

A nanoparticle composition of buckminsterfullerene bonded with epicatechin or a galloyl functional group such as in epigallocatechin gallate, or in tannic acid, is provided that is anti-microbial and efficacious to maintain or re-establish benign healthy cellular homeostasis. In addition, the ability to penetrate hydrophobic malignant microbes via desulfurization is promoted with the addition of phosphonate pendant groups. This further enables the composition to prevent or to treat chronic obstructive pulmonary disorder (COPD), to penetrate fungal spores, and to penetrate the hydrophobic regions of uncontrolled invasive pathological bacteria. The composition can be produced at low temperatures through reactive shear milling. Delivery methods include ingestion, topical application, topical buccal application, inhalation, or injection when used as a medicament or as a food supplement. 1. A nanoparticle composition comprising:buckminsterfullerene (C60) bonded to a molecule that either includes at least one galloyl group or is epicatechin.2. The nanoparticle composition of wherein a bond between the C60 and the molecule is a pi bond.3. The nanoparticle composition of wherein the molecule comprises a quinic acid ester having either di-hydroxyphenyl groups or tri-hydroxy phenyl groups.4. The nanoparticle composition of wherein the molecule comprises epicatechin gallate claim 1 , epigallocatechin claim 1 , or epigallocatechin gallate.5. The nanoparticle composition of wherein the molecule comprises penta-m-digalloyl-glucose.6. The nanoparticle composition of wherein the C60 is further bonded to a disodium phosphonate functional group.7. The nanoparticle composition of wherein the C60 is bonded to the disodium phosphonate functional group and further bonded to four additional phosphonate functional groups.8. The nanoparticle composition of further comprising a zeolite claim 1 , wherein the C60 bonded to the molecule is disposed within the zeolite.9. The nanoparticle ...

MODIFIED METAL NANOPARTICLE AND PHARMACEUTICAL COMPOSITION

A modified metal nanoparticle comprising a metal nanoparticle and a cyclic polyether modifying the metal nanoparticle. 1. A modified metal nanoparticle , comprising:a metal nanoparticle; anda cyclic polyether modifying the metal nanoparticle.2. The modified metal nanoparticle according to claim 1 , wherein the metal nanoparticle is a gold nanoparticle or a silver nanoparticle.3. The modified metal nanoparticle according to claim 1 , wherein an average particle size of the metal nanoparticle is 1 to 1000 nm.4. The modified metal nanoparticle according to claim 1 , wherein the cyclic polyether is a cyclic polyethylene oxide.5. The modified metal nanoparticle according to claim 1 , wherein a number average molecular weight of the cyclic polyether is 500 to 20000.6. The modified metal nanoparticle according to claim 1 , whereinthe metal nanoparticle is a gold nanoparticle, anda mass ratio of the cyclic polyether to the gold nanoparticle is 50 to 1500.7. The modified metal nanoparticle according to claim 1 , whereinthe metal nanoparticle is a silver nanoparticle, anda mass ratio of the cyclic polyether to the silver nanoparticle is 0.1 to 50.8. A pharmaceutical composition comprising the modified metal nanoparticle according to .9. The pharmaceutical composition according to claim 8 , wherein the pharmaceutical composition is a radiosensitizer claim 8 , a photothermal therapeutic agent claim 8 , or an MRI contrast agent. The present invention relates to a modified metal nanoparticle and a pharmaceutical composition comprising the modified metal nanoparticle.Conventionally, metal nanoparticles have been applied in applications such as biosensors, intracellular probes, drug delivery substances, and optical contrast substances. For example, Patent Literature 1 discloses the use of metal nanoparticles as a pharmaceutical composition used for radiotherapy.Patent Literature 1 Japanese Unexamined Patent Publication No. 2012-532847However, conventional metal nanoparticles are ...

CAPSULE FOR DRUG DELIVERY SYSTEMS OF TARGETED TISSUE-SPECIFIC DELIVERY TYPE USING CARBOSILANE DENDRIMER

The present invention relates to a targeting-type capsule for drug delivery systems. The present invention addresses the problem of providing a capsule for drug delivery systems by utilizing the reactivity of a thiol with an alkyl halide, wherein the capsule comprises a silole-containing carbosilane dendrimer and a labeling protein containing a target recognition site (e.g., green fluorescent protein), can include a biological polymer or another molecule therein, and can deliver the biological polymer or the like selectively into a target cell. 110-. (canceled)12. The endocytosis enhancing agent according to the claim 11 , wherein the capsule has the diameter from 50 to 500 nm size.13. The endocytosis enhancing agent according to the claim 11 , wherein said aqueous solvent is saline claim 11 , phosphate buffered saline claim 11 , Tris-HCl buffer claim 11 , HEPES buffer claim 11 , sodium citrate buffer claim 11 , and carbonate-bicarbonate buffer.14. The endocytosis enhancing agent according to the claim 11 , wherein said peptide has both functions to deliver the capsule to a tissue specifically claim 11 , and to improve the incorporation the delivered capsule into the cell of the cells; said peptide specifically bounds to the target protein selected from the group consisting of a surface antigen claim 11 , receptor claim 11 , gate claim 11 , transporter and channel claim 11 , all of them are expressed on the target tissue.17. The endocytosis enhancing agent according to the claim 11 , wherein said target tissue is any one of tissue selected from the group consisting of the normal tissue having inflammation claim 11 , the tissue including the cells having undesirable gene expressions claim 11 , the tissue composed of the cells having undesirable gene expressions claim 11 , and the tissue composed of tumor cells19. The endocytosis enhancing agent according to the claim 18 , wherein said fluorescent protein is any one of selected from the group consisting of red ...

DRUG CONJUGATES WITH PHOTOCLEAVABLE SOLUBILITY MODULATORS

The present invention is directed to a composition suitable for forming an implanted light activated drug depot, methods of making the composition, and methods and systems for using the composition. The composition comprises a plurality of drug conjugates, which comprise a drug molecule and a small solubility modulating portion. The drug conjugates are insoluble upon implantation as a drug depot into a subject, and the drug is preferably soluble once cleaved from the depot. One aspect of the invention is directed to a drug conjugate having a modulating portion that modifies the solubility of the drug conjugate by employing a hydrophobic non-polar moiety. Another aspect of the invention is directed to a drug conjugate having a modulating portion that modifies the solubility of the drug by employing a charged moiety that shifts the isoelectric point of the drug conjugate to a physiological pH. 1. A composition for forming an implanted drug depot , said composition comprising a plurality of drug conjugates , wherein said drug conjugates comprise: a biocompatible, bioresorbable moiety; and', 'a photocleavable group linked to said moiety; and', 'a drug molecule linked to said photocleavable group of said modulating portion;, 'a solubility modulating portion comprisingwherein said drug conjugates are insoluble at physiological pH.2. The composition of claim 1 , wherein said moiety and modulating portion has a molecular weight of 2000 or less claim 1 , preferably 1500 or less claim 1 , more preferably 1000 or less.3. The composition of claim 1 , wherein said moiety is insoluble at physiological pH.4. The composition of claim 1 , wherein said moiety is non-polar.5. The composition of claim 4 , wherein said moiety is a peptide comprising 20 or fewer non-polar amino acids claim 4 , preferably 15 or fewer claim 4 , 10 or fewer claim 4 , or 5 or fewer non-polar amino acids.6. The composition of claim 5 , wherein said moiety comprises 3 non-polar amino acids.7. The composition ...

Polypeptide connected with an organic residue

The invention relates to a method for producing a polypeptide which is modified with an organic group, wherein a bioactive polypeptide is covalently bound to an organic group that comprises a backbone structure having aromatic side chains, thereby forming a modified polypeptide which is constituted of the bioactive polypeptide and the group having aromatic side chains. At least one of the aromatic side chains of the group is subjected to chemical or enzymatic hydroxylation.

Targeting multiple receptors on a cell surface for specific cell targeting

A method of delivering a cargo agent into cytosol of a cell can include: providing the delivery system of one of the embodiments described herein having the first and second delivery platforms; and administering the delivery system to a cell so as to cause targeting of two features on the cell so as to: cause endocytosis of the first and second delivery platforms of the delivery system into a common endosome, destabilize the endosome of the cell having the delivery system, release the cargo agent from the second linker; and release the cargo agent from the destabilized endosome into cytosol of the cell. A method of treating a disease can include: performing the method of method of delivering a cargo agent into cytosol of a cell in a subject having a disease, wherein the cargo agent is a therapeutic agent for the disease.

FUNCTIONALIZED NANOMATERIALS

A functionalized nanomaterial, such as a nanoparticle, can include a polythioaminal functionalized surface. The polythioaminal linked to the surface of the nanomaterial can be bonded to a compound such as therapeutic and/or diagnostic materials. The thiol-based linkages can be used to bond the polythioaminal to both the nanomaterial and the therapeutic and/or diagnostic materials. Polythioaminals can be prepared via reactions of triazine and dithiols. Polythioaminals thus prepared can be further modified to provide linkages to the nanomaterial and other compounds such as medicinal compound, peptides, and dyes. Nanomaterials including such compounds linked thereto via the polythioaminal can be supplied for therapeutic and/or diagnostic purposes to biological target regions. 2. The material of claim 1 , wherein X comprises a theranostic compound.3. The material of claim 2 , wherein the theranostic compound includes a dye molecule.4. The material of claim 2 , wherein the theranostic compound is a fluorescent dye.5. The material of claim 2 , wherein the theranostic compound includes a biologically active species.6. The material of claim 2 , wherein the theranostic compound is a therapeutic agent.7. The material of claim 2 , wherein the theranostic compound is a peptide.8. The material of claim 1 , wherein the nanomaterial is a nanoparticle.9. The material of claim 1 , wherein the nanomaterial is a metal nanoparticle.10. The material of claim 1 , wherein at least one instance of le includes a polyethylene glycol.11. The material of claim 1 , wherein Z includes at least one carbon atom.12. The material of claim 1 , wherein Z is a n-hexyl group.13. The material of claim 1 , whereinthe nanomaterial is a gold nanoparticle,at least one instance of le comprises a polyethylene glycol,{'sup': '2', 'Ris a methyl group,'}Z includes at least one carbon atom, andX comprises a peptide or a nucleotide.14. The material of claim 1 , whereinthe nanomaterial is a gold nanoparticle,at ...

BIOCONJUGATES OF NEUROPEPTIDES DERIVATIVES

A bioconjugate including at least one neuropeptide covalently bond to at least one hydrocarbon compound of squalene structure. 2. The bioconjugate according to claim 1 , wherein the at least one hydrocarbon compound of squalene structure comprises from 11 to 102 carbon atoms.3. The bioconjugate according to claim 1 , wherein the at least one hydrocarbon compound of squalene structure is squalenic acid and derivatives thereof claim 1 , the derivative of squalenic acid being selected 1 claim 1 ,1′ claim 1 ,2-tris-nor-squalenic acid claim 1 , 1 claim 1 ,1′ claim 1 ,2-tris-nor-squalenamine claim 1 , 1 claim 1 ,1′ claim 1 ,2-tris-nor-squalenol claim 1 , 1 claim 1 ,1′ claim 1 ,2-tris-nor-squalenethiol claim 1 , squalene acetic acid claim 1 , squalenylethanol claim 1 , squalenylethanethiol and squalenylethylamine.4. The bioconjugate according to claim 1 , wherein the at least one neuropeptide is an opioid peptide.5. The bioconjugate according to claim 4 , wherein the opioid peptide is selected among the group comprising leucine enkephalin (LENK) claim 4 , methionine enkephalin (MENK) claim 4 , dalargin claim 4 , kyotorphin claim 4 , endomorphins claim 4 , endorphins or a derivative thereof.6. The bioconjugate according to claim 1 , wherein the at least one neuropeptide and the at least one hydrocarbon compound of squalene structure are bond either to each other via a covalent bond or via a spacer or a function of the ester claim 1 , disulfur claim 1 , phosphate or amide bond.7. The bioconjugate according to claim 6 , wherein the spacer is selected among the group comprising dioxycarbonyl claim 6 , diglycolate claim 6 , carbonate claim 6 , carbamate and amide spacer.9. The bioconjugate according to for use as a drug claim 1 , preferably as an anti-hyperalgesic drug.10. The bioconjugate according to for use in the treatment of pain disorders.11. A nanoparticle comprising the bioconjugate according to .12. The nanoparticle according to claim 11 , wherein the nanoparticle ...

Membrane-penetrating peptides to enhance transfection and compositions and methods for using same

The present invention is directed to non-naturally occurring peptides containing a membrane-penetrating amino acid sequence and further at least one polycationic moiety or peptide sequence. The peptides are suitable for use in delivery a cargo to the interior of a cell. Suitable cargo includes nucleic acid molecules (including DNA, RNA or PNA), polypeptides, or other biologically active molecules. The present invention is further directed to transfection complexes containing the non-naturally occurring peptides of the present invention in non-covalent association with at least one cationic lipid and a cargo to be delivered to the interior of a cell. The invention further relates to methods for the preparation and use of the non-naturally occurring peptides for the formation of transfection complexes and the delivery of a cargo to the interior of a cell in culture, an animal or a human. The invention also relates to compositions and kits useful for transfecting cells.

Press for Drill Cuttings

A press comprising a body, the body containing a chamber interposed between a ram and an end wall, the ram connected to a piston to compact material against the end wall to generate a pressed object, the chamber comprising an opening for loading the material into the chamber, and a series of perforations to enable liquid contained in the material to be expelled from the chamber during advancement of the piston towards the end wall. 1. A press comprising a body , the body containing a chamber interposed between a ram and an end wall , the ram connected to a piston to compact material against the end wall to generate a pressed object , the chamber comprising an opening for loading the material into the chamber , and a series of perforations to enable liquid contained in the material to be expelled from the chamber during advancement of the piston towards the end wall.2. The press of claim 1 , wherein the end wall is provided by an end cap coupled to the chamber claim 1 , the end cap movable to provide an opening into the chamber to expel the pressed object.3. The press of claim 2 , wherein the end cap is rotatably attached to the chamber.4. The press of claim 1 , wherein the chamber comprises an access mechanism adjacent the end wall to facilitate removal of the pressed object.5. The press of claim 1 , further comprising at least one additional chamber and at least one additional piston for compacting the material within both chambers.6. The press of claim 5 , comprising a single end cap for both the chamber and the at least one additional chamber.7. The press of claim 1 , wherein the pressed object comprises drill cuttings and at least some fluid to be expelled through the series of perforations.8. A system for recovering drilling fluid from drill cuttings claim 1 , the system comprising:a first collection tank for collecting drill cuttings output from a shale shaker;a conveyance system for conveying the drill cuttings to a press;the press comprising a body, the body ...

Beverage Gasification System

A beverage gasification system for concurrently extracting solid particulates from a solution of a liquid and a gas and increasing absorption of the gas into the liquid, in which a particle separator is located downstream of a gas supply assembly. A method of forming a clarified gasified beverage is also disclosed, in which gas is injected into the liquid at a location upstream of the point at which solids are removed from the liquid. 1. A beverage gasification system , the system comprising:a liquid supply source including a pump, wherein the liquid supply source provides a liquid containing solid particulates therein;the liquid supply source having a downstream outlet in fluid communication with a gas supply arrangement, wherein the gas supply arrangement is configured to introduce a gas into the liquid to form a solution of liquid and gas; anda particle separator separate from and located downstream of the pump of the liquid supply source and downstream of the gas supply arrangement; wherein the particle separator includes an inlet and an outlet, wherein the solution of liquid and gas is supplied to the inlet of the particle separator and wherein the particle separator is operable independently of the pump between the inlet and outlet of the particle separator to concurrently extract the solid particulates from the solution and increase absorption of the gas into the liquid to form a clarified gasified liquid at the outlet of the particle separator.2. The beverage gasification system of claim 1 , wherein the particle separator is a centrifuge.3. (canceled)4. A beverage gasification system claim 1 , the system comprising:a liquid supply source configured to provide a liquid containing solid particulates therein;the liquid supply source having a downstream outlet in fluid communication with a gas supply arrangement, wherein the gas supply arrangement is configured to introduce a gas into the liquid to form a solution of liquid and gas; anda particle separator ...

WINE AERATOR AND METHOD OF AERATING WINE

A wine aerator includes a container having walls bounding an interior compartment. The compartment has an open condition in which a volume of a type of wine to be aerated is admitted to partially fill the compartment, and a closed condition for hermetically sealing the wine in the compartment. The remainder of the compartment contains a volume of air. A plurality of indicators are provided on the container for visually indicating different air/wine volume ratios based on the type of wine in the compartment. An agitator agitates the hermetically sealed wine with a selected one of the ratios for a predetermined time to aerate the wine. 1. An aerator for wine , comprising:a container having walls bounding an interior compartment, the compartment having an open condition in which a volume of a type of wine to be aerated is admitted to partially fill the compartment, and a closed condition for hermetically sealing the wine in the compartment, the remainder of the compartment containing a volume of air;a plurality of indicators on the container for visually indicating different air/wine volume ratios based on the type of wine in the compartment; andan agitator for agitating the hermetically sealed wine with a selected one of the ratios for a predetermined time to aerate the wine.2. The wine aerator of claim 1 , wherein the indicators are spaced apart at different elevations along an upright axis claim 1 , and wherein the container has a wall movable along the upright axis among the elevations to select one of the ratios.3. The wine aerator of claim 2 , and a wine level line on the container for visually indicating a wine level of the wine in the compartment claim 2 , and wherein the indicators are wine type lines for visually indicating the different elevations to which the wall is to be moved based on the type of wine in the compartment.4. The wine aerator of claim 2 , wherein the compartment has an inner surface;wherein the movable wall has a periphery; and a seal ...

Product Display Container

An apparatus is provided for a collapsible product display container that may be shipped or stored in two main pieces, but which may be assembled at the point of sale by reversible attachment of four side walls to a pallet bottom. The four side walls are hingedly interconnected to each other and are attachable to the pallet bottom in an upright vertical relationship without bolts, screws, or other separate hardware. The container further comprises an advertisement display case that is connected to the back side wall by a hinge and may be moved into a vertical planar alignment above the back side wall of the container by hinging mechanism for marketing purposes. 1. A collapsible product display container , comprising:a pallet bottom configured to allow lifting and moving of the display container;four side walls that may be reversibly attached to the pallet bottom;clamping attachment protrusions rigidly affixed to the pallet bottom;wherein the four side walls may be reversibly attached to the pallet bottom using the clamping attachment protrusions to hold the four side walls in a vertical upright position in relation to the pallet bottom such that the assembled container will have the shape of a rectangular cuboid that is open at the top;wherein the four side walls are reversibly attachable to the pallet bottom without screws, bolts, or pins.2. The container of claim 1 , wherein the four side walls are permanently hingedly interconnected such that they may be folded substantially flat or they may be pulled apart into a substantially rectangular configuration and then attached in that substantially rectangular configuration to the pallet bottom using the clamping attachment protrusions such that the four side walls while in the substantially rectangular configuration will be attached to the pallet bottom in a vertical upright alignment in relation to the pallet bottom and will serves as the sides of the container.3. The container of claim 1 , wherein the four side ...

PROGRAMMABLE DENDRITIC DRUGS

Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I) or a stereoisomer, tautomer or salt thereof, wherein R, R, R, L, L, L, L, L, L, L, M, m, and p are as defined herein. Methods associated with preparation and use of such compounds is also provided. 3. The compound of any one of or , wherein Lis a heteroalkylene linker.5. The compound of claim 4 , wherein Lis at each occurrence claim 4 , independently a heteroalkylene linker.6. The compound of claim 5 , wherein Lis at each occurrence claim 5 , independently an alkylene oxide linker.8. The compound of claim 7 , wherein z is an integer from 3 to 6.9. The compound of any one of - claim 7 , wherein Land Lare claim 7 , at each occurrence claim 7 , independently absent claim 7 , C-Calkylene claim 7 , C-Calkenylene or C-Calkynylene.12. The compound of claim 11 , wherein y is 2.13. The compound of any one of - claim 11 , wherein at least one occurrence of x claim 11 , x claim 11 , xor xis 1.14. The compound of any one of - claim 11 , wherein x claim 11 , x claim 11 , xand xare each 1 at each occurrence.15. The compound of any one of - claim 11 , wherein xand xare 0 at each occurrence.16. The compound of any one of - claim 11 , wherein m is claim 11 , at each occurrence claim 11 , independently an integer from 0 to 50.17. The compound of any one of - claim 11 , wherein at least one occurrence of m is 0.18. The compound of any one of - claim 11 , wherein n is claim 11 , at each occurrence claim 11 , independently an integer from 1 to 10.19. The compound of any one of - claim 11 , wherein p is claim 11 , at each occurrence independently an integer from 1 to 10.20. The compound of any one of - claim 11 , wherein at least one occurrence of p is 1 claim 11 , 2 claim 11 , 3 or 4.21. The compound of any one of - claim 11 , wherein q is claim 11 , at each occurrence claim 11 , independently an integer from 1 to 10.22. The compound of any one of - claim 11 , wherein L′ is a ...

POLY(CYCLIC IMINO ETHER)S

The invention relates to invention relates to a statistical copolymer represented by the following formula (I): Ini-[Ox]-[Oz]-Nuc (I) wherein: Ini represents a residue of an initiator of cationic polymerization, Nuc represents a residue of a nucleophilic agent, Ox represents N(R)CHRCHR; each Rindependently represents H or C(O)R; and Rindependently represents optionally substituted Calkyl, optionally substituted cycloalkyl, optionally substituted aralkyl or optionally substituted aryl; Oz represents N(R)CHRCHRCHR; each Rindependently represents C(O)Ror H; and Rindependently represents optionally substituted Calkyl, optionally substituted cycloalkyl, optionally substituted aralkyl or optionally substituted aryl; each Rindependently represents H, linear or branched Calkyl; m≥5; n≥5; m+n≥20; 3:97≤m:n≤97:3. The statistical copolymers of the present invention exhibit useful properties that can be exploited in the medical field, especially in polymer micelles for drug delivery and polyplexes for DNA delivery. 115-. (canceled)16. A statistical copolymer represented by the following formula (I):{'br': None, 'sub': m', 'n, 'Ini-[Ox]-[Oz]-Nuc \u2003\u2003(I)'} (a) Ini represents a residue of an initiator of cationic polymerization,', '(b) Nuc represents a residue of a nucleophilic agent,', {'sup': 1', 'a', 'a', '1', '11, '(c) Ox represents N(R)CHRCHR; each Rindependently represents H or C(O)R; and'}, {'sup': '11', 'sub': '1-12', 'Rindependently represents optionally substituted Calkyl, optionally substituted cycloalkyl, optionally substituted aralkyl or optionally substituted aryl;'}, {'sup': 2', 'a', 'a', 'a', '2', '21', '21, 'sub': '1-12', '(d) Oz represents N(R)CHRCHRCHR; each Rindependently represents C(O)Ror H; and Rindependently represents optionally substituted Calkyl, optionally substituted cycloalkyl, optionally substituted aralkyl or optionally substituted aryl;'}, {'sup': 'a', 'sub': '1-3', '(e) each Rindependently represents H, linear or branched Calkyl;'}, '(f) m≥ ...

FLAVOR SYSTEM AND METHOD FOR MAKING SHERRY WINE LIKE BEVERAGES

A method of making a sherry wine-like beverage includes combining water, ethanol and a plurality of flavor compounds in an amount sufficient to impart the flavor of a sherry wine without the need for fermentation and/or aging. 1. A method of making a sherry wine-like beverage comprising:adding at least one flavor compound selected from a first group of compounds to a quantity of aqueous solution, the first group of compounds consisting of caprylic acid, isobutyric acid, butyric acid, 3-methylbutyric acid, isovaleric acid, caproic acid, and decanoic acid, wherein the at least one flavor compound selected from the first group is added in an amount ranging from about 2 μg/L to about 400,000 μg/L;adding at least one flavor compound from a second group of compounds to the quantity of aqueous solution, the second group consisting of 2-methylbutanol, isoamyl alcohol, diacetyl, vanillin, methylpropanol, isovaleraldehyde, 2-methylpropanal, 2-methylbutanal, 4-hydroxy-2,5-dimethylfuran-3(2H)-one, acetovanillone, 2,3-pentanedione, and ethylfuraneol, wherein the at least one flavor compound selected from the second group is added in an amount ranging from about 0.05 μg/L to about 4,000,000 μg/L;adding at least one flavor compound from a third group of compounds to the quantity of aqueous solution, the third group consisting of 2-phenylethanol, phenylacetic acid, 2-phenylethyl acetate, and linalool, wherein the at least one flavor compound selected from the third group is added in an amount ranging from about 0.1 μg/L to about 1,000,000 μg/L;adding at least one flavor compound from a fourth group of compounds to the quantity of aqueous solution, the fourth group consisting of acetaldehyde, butanoic acid ethyl ester, ethyl isobutyrate, octanoic acid ethyl ester, hexanoic acid ethyl ester, ethyl isovalerate, 2-methylbutanoic acid ethy ester, (E)-β-damascenone, 1,1-diethoxyethane, propanoic acid ethyl ester, (L)-ethyl-2-ethyl lactate, ethyl DL-leucate, 3-methylbutyl acetate, and ...

PHARMACEUTICAL PRODRUGS AND METHODS OF THEIR PREPARATION AND USE

The disclosure provides compounds of Formula (I), wherein X, Y, and Z are defined herein. The disclosure also provides particles comprising one or more compounds described herein, compositions comprising one or more compounds or particles described herein and a pharmaceutically acceptable carrier, and methods of treating a subject in need thereof comprising administering one or more compounds, particles, or compositions described herein to the subject. 2. The compound of claim 1 , wherein the partition coefficient (log P) of the water-soluble claim 1 , biologically active compound is about 7 or less.3. The compound of claim 1 , wherein the log P of the compound is about 7 or greater.4. The compound of any one of the preceding claims claim 1 , wherein the water-soluble claim 1 , biologically active compound is an anti-inflammatory agent claim 1 , anti-psychotic agent claim 1 , anti-viral agent claim 1 , chemotherapeutic agent claim 1 , or dopamine modulating agent claim 1 , or is indicated for the treatment of migraine or pain.5. The compound of any one of the preceding claims claim 1 , wherein the water-soluble biologically active compound is actinomycin claim 1 , azacitidine claim 1 , belinostat claim 1 , bendamustine claim 1 , bleomycin claim 1 , bortezomib claim 1 , cabazitaxel claim 1 , cadarbazine claim 1 , cladribine claim 1 , clofarabine claim 1 , cytarabine claim 1 , cyproterone claim 1 , daunorubicin claim 1 , decitabine claim 1 , docetaxel claim 1 , doxorubicin claim 1 , epirubicin claim 1 , eribulin claim 1 , etoposide claim 1 , floxuridine claim 1 , fludarabine claim 1 , gemcitabine claim 1 , idarubicin claim 1 , irinotecan claim 1 , ixabepilone claim 1 , levodopa claim 1 , melphalan claim 1 , methotrexate claim 1 , mitomycin claim 1 , mitoxantrone claim 1 , nelarabine claim 1 , paclitaxel claim 1 , pemetrexed claim 1 , pentostatin claim 1 , pixantrone claim 1 , pralatreate claim 1 , raltitrexed claim 1 , streptozocin claim 1 , temozolomide claim 1 , ...

PROTEIN-POLYMER-DRUG CONJUGATES

A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions are also described. 2. The therapeutic drug and targeting conjugate of claim 1 , wherein the ligand has a molecular weight of greater than about 40 kD and the PHF has a molecular weight ranging from about 2 kDa to about 40 kDa.3. The therapeutic drug and targeting conjugate of claim 1 , wherein the ligand comprises an immunoglobulin or a functional fragment thereof.4. The therapeutic drug and targeting conjugate of claim 3 , wherein the immunoglobulin or functional fragment thereof is selected from the group consisting of a monoclonal antibody claim 3 , a chimeric antibody claim 3 , a humanized antibody claim 3 , a human antibody claim 3 , an immunoadhesin claim 3 , a F(Ab) claim 3 , a minibody claim 3 , Fab′ claim 3 , a single-domain antibody claim 3 , a nanobody claim 3 , a single chain Fv claim 3 , a tandem/bis-scFv claim 3 , a F(ab) claim 3 , a scFv-Fc (or scFvFc) claim 3 , a dsFv claim 3 , a diabody claim 3 , a triabody claim 3 , and a tetrabody.5. The therapeutic drug and targeting conjugate of claim 4 , wherein the immunoglobulin or a functional fragment thereof is an anti-5T4 scFvFc and has the amino acid sequence of SEQ ID NO: 7.6. The therapeutic drug and targeting conjugate of claim 1 , wherein mis 2 to 8.7. The therapeutic drug and targeting conjugate of claim 6 , wherein mis 2 to 4.8. The therapeutic drug and targeting conjugate of claim 7 , D is independently selected from the group consisting of (a) an auristatin and its analogs; (b) a calicheamicin and its derivatives; (c) duocarmycin and its analogs; (d) SN38 claim ...

METHODS OF TREATING CANCER

The present invention relates to methods of treating or preventing cancer in a subject in need thereof comprising administering a therapeutically effective amount of a compound of the invention. 24-. (canceled)5. The method of claim 1 , wherein the FXR agonist is Compound 1 or a pharmaceutically acceptable salt thereof.6. The method of claim 5 , wherein the FXR agonist is the sodium salt of Compound 1.7. The method of claim 5 , wherein the FXR agonist is the N N-diethylethaneamine salt of Compound 1.8. The method of claim 1 , wherein the FXR agonist is Compound 2 or a pharmaceutically acceptable salt or amino acid conjugate thereof.9. The method of claim 8 , wherein the FXR agonist is the glycine conjugate of Compound 2.10. The method of claim 8 , wherein the FXR agonist is the taurine conjugate of Compound 2.11. The method of claim 8 , wherein the FXR agonist is the sarcosine conjugate of Compound 2.1416-. (canceled) Cancer is characterized primarily by an increase in the number of abnormal cells derived from a given normal tissue, invasion of adjacent tissues by the abnormal cells, or lymphatic or blood-borne spread of malignant cells to regional lymph nodes and to distant sites (metastasis). Clinical data and molecular biologic studies indicate that cancer is a multistep process that begins with minor pre-neoplastic changes, which may under certain conditions progress to neoplasia.Primary liver cancer is one of the most common forms of cancer in the world. There are two main types of liver cancer: hepatocellular carcinoma (HCC), also known as malignant hepatoma, and cholangiocellular carcinoma, also known as cholangiocarcinoma (CCA). HCC is the most common form of primary liver cancer, and develops within the hepatocyte. HCC occurs mostly in men and patients that suffer from cirrhosis. HCC is the one of the most common cancers worldwide and the third most common cause of cancer-related deaths. The disease is often diagnosed late in the course of clinical ...

BORONIC ESTER PRODRUGS AND USES THEREOF

Disclosed herein are compounds of Formula (I) or (II). The compounds include an agent (e.g., pharmaceutical agent, cosmetic agent, or nutraceutical agent) through a linker that includes a boronic ester moiety in the backbone of the linker. The compounds may be monomers. Also provided are polymers prepared by polymerizing the monomers. The polymers may be useful for delivering the agent to a subject, tissue, biological sample, or a cell. Also provided are methods of preparing the polymers, compositions and kits comprising the polymers, and methods of use (e.g., use in delivering the agent, treating a disease, preventing a disease, diagnosing a disease) involving the polymers or compositions. The structure of the boronic ester moiety may be fine tuned so that the properties related to delivery to a subject, biological sample, tissue, or cell may be fine tuned. 3. (canceled)4. The compound of claim 1 , or a salt thereof claim 1 ,{'sub': '3', 'wherein X is —N.'}522-. (canceled)2450-. (canceled)5268-. (canceled)69. The compound of claim 1 , or a salt thereof claim 1 , wherein at least one instance of the agent is bortezomib.7073-. (canceled)77. A method of preparing a polymer comprising polymerizing a compound of claim 1 , or a salt thereof claim 1 , wherein X is a polymerization handle.7882-. (canceled)83. A method of preparing a polymer comprising reacting an existing polymer with a compound of claim 1 , or salt thereof claim 1 , wherein the existing polymer comprises a reaction handle able to react with X claim 1 , and in the step of reacting claim 1 , the reaction handle able to react with X is reacted with X.8485-. (canceled)86. A polymer prepared by a method of .87. A composition comprising:{'claim-ref': {'@idref': 'CLM-00002', 'claim 2'}, 'a polymer of ; and'}optionally an excipient.8889-. (canceled)90. A kit comprising:{'claim-ref': {'@idref': 'CLM-00002', 'claim 2'}, 'a polymer of ; and'}instructions for using the polymer.91. A method of delivering an agent to a ...

LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

The present invention relates to a ligand-drug conjugate of an exatecan analogue, a preparation method therefor and an application thereof. Specifically, the present invention provides a ligand-drug conjugate having a structure shown in formula (-D), a preparation method therefor, a pharmaceutical composition containing same, and use thereof in preparation of drugs for treating cancers by means of receptor regulation. The definition of each substituent in formula (-D) is the same as that in the description. 47.-. (canceled)8. The ligand-drug conjugate or the pharmaceutically acceptable salt or solvate thereof according to claim 3 , wherein n is 2 to 8 claim 3 , which can be an integer or a decimal.9. The ligand-drug conjugate or the pharmaceutically acceptable salt or solvate thereof according to claim 3 , wherein the linker unit -L- is -L-L-L-L- claim 3 ,{'sup': 1', '3, 'sub': 2', '1-8', '1-8', '1-8, 'Lis selected from the group consisting of -(succinimide-3-yl-N)—W—C(O)—, —CH—C(O)—NR—W—C(O)— and —C(O)—W—C(O)—, wherein W is selected from the group consisting of Calkyl, Calkyl-cycloalkyl and linear heteroalkyl comprising 1 to 8 atom(s), the heteroalkyl comprises 1 to 3 heteroatom(s) selected from the group consisting of N, O and S, wherein the Calkyl, cycloalkyl and linear heteroalkyl are each independently optionally further substituted by one or more substituent(s) selected from the group consisting of halogen, hydroxy, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl;'}{'sup': 2', '4', '1', '4', '1', '1', '1, 'sub': 2', '2', '2', '2', '2', '2', '2', '2, 'Lis selected from the group consisting of —NR(CHCHO)pCHCHC(O)—, —NR(CHCHO)pCHC(O)—, —S(CH)pC(O)— and a chemical bond, wherein pis an integer from 1 to 20;'}{'sup': '3', 'Lis a peptide residue composed of 2 to 7 amino acids, wherein the amino acids are optionally further substituted by one or more substituent(s) selected from the group consisting of halogen, hydroxy, cyano, amino, alkyl, ...

Multifunctional coupling reagents having an azlactone function

Novel compounds, having an azlactone function, of formula (I), to be used as multifunctional coupling agents, and a method for coupling a biomolecule and a target molecule using such a compound are described. A diagnosis reagent, a kit for implementing the coupling method, a method for separating, detecting and/or characterizing at least one molecule of interest, and a composition including a novel compound are also described.

OLIGOMERS

Certain disclosed oligomers induce exon skipping during processing of myostatin pre-mRNA. The oligomers may be in a vector or encoded by the vector. The vector is used for inducing exon skipping during processing of myostatin pre-mRNA. A therapeutically effective amount of the oligomer may be administered to a subject patient such that exon skipping during processing of myostatin pre-mRNA is induced. The administration to a subject may be used in order to increase or maintain muscle mass, or slowing degeneration of muscle mass in the subject. The administration to a subject may ameliorate muscle wasting conditions, such as muscular dystrophy. Examples of such muscular dystrophies which may be so treated include Becker's muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy, myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy. 2. The pharmaceutical composition of claim 1 , wherein the oligomer causes an exon skipping rate of at least 40%.3. The pharmaceutical composition of claim 1 , wherein the oligomer causes an exon skipping rate of at least 90%.4. (canceled)5. The pharmaceutical composition of claim 1 , wherein the oligomer is a phosphorodiamidate morpholino oligonucleotide (PMO).6. The pharmaceutical composition of claim 1 , wherein the oligomer is between 20 and 40 bases in length.7. The pharmaceutical composition of claim 1 , wherein the oligomer is about 30 bases in length.8. The pharmaceutical composition of claim 1 , wherein the base sequence is selected from SEQ ID NOS. 4 claim 1 , 17 claim 1 , and 18.911.-. (canceled)12. The pharmaceutical composition of claim 1 , wherein the oligomer is conjugated to or complexed with a distinct chemical entity.13. (canceled)14. A method of inducing exon skipping during processing of myostatin pre-mRNA in a patient claim 1 , the method ...

GAS-INFUSED FLUIDS AND METHODS OF MAKING AND USING SAME

The present disclosure provides fluids, such as a distilled spirit, comprising at least about 25 ppm of an infused gas. Systems and methods for producing such gas-infused fluids are also provided. 1. (canceled)2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. (canceled)8. (canceled)9. (canceled)10. (canceled)11. (canceled)12. (canceled)13. (canceled)14. (canceled)15. (canceled)16. (canceled)17. (canceled)18. (canceled)19. (canceled)20. (canceled)21. (canceled)22. (canceled)23. (canceled)24. (canceled)25. (canceled)26. (canceled)27. (canceled)28. (canceled)29. (canceled)30. (canceled)31. (canceled)32. (canceled)33. (canceled)34. (canceled)35. (canceled)36. (canceled)37. (canceled)38. (canceled)39. (canceled)40. (canceled)41. A method of infusing oxygen in a distilled spirit comprising;(a) containing a fluid within a gas infusion chamber; wherein the gas infusion chamber comprises a micromembrane having a pore channel diameter of about 0.05 μm to about 5.0 μm;(b) pressurizing the gas infusion chamber with oxygen gas;(c) contacting the fluid with the oxygen gas in the gas infusion chamber to provide an oxygenated fluid comprising at least about 25 ppm of oxygen; and(d) removing the oxygenated fluid from the gas infusion chamber.42. The method of claim 41 , wherein the step of pressurizing comprises pressurizing the gas infusion chamber to about 15 psi to about 100 psi.43. The method of further comprising circulating the fluid in the gas infusion chamber.44. The method of claim 43 , wherein the step of circulating comprises passing the fluid from a holding tank through the gas infusion chamber a plurality of times.45. The method of further comprising releasing the oxygen gas from the gas infusion chamber and pressurizing the gas infusion chamber with a second gas.46. The method of claim 45 , wherein the second gas is nitrogen or carbon dioxide.47. The method of further comprising releasing the second gas from the gas infusion chamber and pressurizing ...

EXPRESSION VECTOR DELIVERY SYSTEM AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE

Embodiments of a novel system for delivering an expression vector encoding an antigen to a subject that allows for spatiotemporal control over stimulation of the subject's immune response to the antigen are provided. In some embodiments, the expression vector delivery system includes a polymer linked to an adjuvant in prodrug form that can form polymer nanoparticles and enter a cell (such as an immune cell) under physiological conditions. In some embodiments, the adjuvant is linked to the polymer by an enzyme degradable labile bond, the cleavage of which activates the adjuvant to stimulate an immune response. 1. A method of inducing an immune response to an antigen in a subject , comprising:administering locally to a target location in the subject a therapeutically effective amount of an immunogenic composition comprising a polymer linked to an adjuvant prodrug and an expression vector comprising a nucleic acid molecule encoding the antigen; whereinthe polymer linked to the adjuvant prodrug and the expression vector form polymer nanoparticles in the immunogenic composition;the polymer nanoparticles can enter cells under physiological conditions; andthe adjuvant prodrug comprises an enzyme-degradable labile bond, wherein cleavage of the enzyme-degradable labile bond by an intracellular enzyme activates the adjuvant prodrug to induce the immune response to the antigen in the subject.2. The method of claim 1 , wherein the expression vector is a DNA plasmid expression vector that does not comprise any CpG motifs.3. The method of claim 1 , wherein the polymer is linked to the adjuvant prodrug via a linker comprising the enzyme-degradable labile bond claim 1 , and cleavage of the enzyme-degradable labile bond by the intracellular enzyme activates the adjuvant and releases the adjuvant from the polymer.4. The method of claim 1 , wherein the polymer is a cationic polymer and the expression vector is linked to the cationic polymer by an electrostatic interaction.5. The ...

SMALL MOLECULE LIGAND-TARGETED DRUG CONJUGATES FOR ANTI-INFLUENZA CHEMOTHERAPY AND IMMUNOTHERAPY

Disclosed herein is a small molecule targeted drug conjugate for anti-influenza chemotherapy and immunotherapy. The disclosed drug conjugate may form an adaptor to recruit additional CAR T cells or other immune cells for precise elimination of influenza virus-infected cells in a subject. Concurrently administered antibodies or pre-existing immunity in influenza-virus infected subject works well with the targeted conjugate to eliminate virus infected cells, saving valuable time for rescuing late stage patients. 1. A conjugate comprising a targeting ligand (TL) for an envelope protein of an influenza virus , a linker (L) and a payload of drug (D) , wherein the TL is a molecule that binds to the envelope protein , the linker is covalently bound to both the D and the TL , and the D is an imaging agent , a therapeutic drug , an immune modulator or the combination thereof.2. The conjugate according to claim 1 , wherein the linker comprises a spacer and a cleavable or noncleavable bridge between the TL and the D.3. The conjugate according to claim 1 , wherein the envelope protein of the influenza virus is Neuraminidase (NA) or Hemagglutinin (HA).4. The conjugate according to claim 1 , wherein the TL is zanamivir.5. The conjugate according to claim 1 , wherein the TL is selected from the group consisting of oseltamivir claim 1 , zanamivir claim 1 , peramivir and laninamivir.6. The conjugate according to claim 1 , wherein the D is selected from the group consisting of Tubulysin B hydrazide claim 1 , pimodivir claim 1 , Ozanimod and SN38.8. The conjugate according to claim 2 , wherein the cleavable bridge contains a disulfide or acid labile bond.9. The conjugate according to claim 8 , wherein the acid labile bond comprises an ester claim 8 , hydrazone claim 8 , oxime claim 8 , acetal claim 8 , ketal claim 8 , phenolic ether claim 8 , or Schiff base bond.10. A method to treat influenza virus infection in a subject claim 8 , comprising providing a conjugate to the subject claim ...

PROTEIN COMPLEX COMPRISING NON-PEPTIDYL POLYMER-COUPLED FATTY ACID DERIVATIVE COMPOUND AS LINKER AND PREPARATION METHOD THEREFOR

Provided are a protein conjugate in which a physiologically active polypeptide is linked to a biocompatible material via a non-peptidyl polymer-coupled fatty acid derivative compound serving as a linker, exhibiting an increased duration of physiological activity compared to natural forms and a preparation method therefor. Since an increase in serum half-life of the physiologically active polypeptide of the protein conjugate, in which the biocompatible material, the non-peptidyl polymer-coupled fatty acid derivative compound, and the physiologically active polypeptide are linked, is proved, the protein conjugate may be widely used in the field of protein drugs. 2. The non-peptidyl polymer-coupled fatty acid derivative compound claim 1 , the stereoisomer thereof claim 1 , or the pharmaceutically acceptable salt thereof according to claim 1 , wherein Rand Rare each independently maleimide claim 1 , N-hydrosuccinimide claim 1 , succinimide claim 1 , formaldehyde claim 1 , acetaldehyde claim 1 , propionaldehyde claim 1 , butylaldehyde claim 1 , orthopyridyl disulfide (OPSS) claim 1 , iodoacetamide claim 1 , halogenated acetamide including bromide claim 1 , fluorine claim 1 , chlorine claim 1 , astatine claim 1 , or tennessine instead of iodine claim 1 , difluorocyclooctyne (DIFO) claim 1 , dibenzocyclooctyne (DIBO) claim 1 , dibenzo-aza-cyclooctyne (DIBAC or DBCO) claim 1 , biarylazacyclooctynones (BARAC) claim 1 , tetramethylthiacycloheptyne (TMTH) claim 1 , bicyclononyne (BCN) claim 1 , Sondheimer diyne claim 1 , cyclooctyne (OCT) claim 1 , monofluorinated cyclooctyne (MOFO) claim 1 , dimethoxyazacyclooctyne (DIMAC) claim 1 , 2 claim 1 ,3 claim 1 ,6 claim 1 ,7-tetramethoxy-DIBO (TMDIBO) claim 1 , sulfonylated DIBO (S-DIBO) claim 1 , carboxymethylmonobenzocyclooctyne (COMBO) claim 1 , pyrrolocyclooctyne (PYRROC) claim 1 , or a Calkynyl.4. The protein complex according to claim 3 , wherein the non-peptidyl polymer-coupled fatty acid derivative compound has two or more ...

Nanoparticles for controlled lysis of blood clots

Fibrinolytic nanoparticles including a polymeric core having a surface that is functionalized with a cationic amphiphilic compound, and a fibrinolytic agent dispersed within the core, are described herein. The fibrinolytic nanoparticles can be used in method of dissolving a blood clot in a subject by administering to the subject a therapeutically effective amount of fibrinolytic nanoparticles.

Light-mediated treatments of metastatic cancers

A method of treating or mitigating metastatic cancer in a subject having a primary tumor, by providing a prodrug system, the prodrug system comprising (1) a prodrug comprising at least one functional moiety and at least one linker linked to the at least one functional moiety, wherein the at least one functional moiety is inactive when linked to the linker, and wherein the at least one linker is cleavable by singlet oxygen, and (2) a sensitizer which when exposed to an activator results in generation of singlet oxygen by the sensitizer, causing cleavage of the at least one linker thereby activating the at least one functional moiety, wherein the sensitizer optionally is linked to the functional moiety via the at least one linker, administering the prodrug system to the subject, and exposing the primary tumor to the activator causing activation of the functional moiety and death of at least a portion of the primary tumor. Also disclosed is a method of making a whole-cell cancer vaccine, and using the vaccine to treat or mitigate metastatic cancer in a subject.

SHORT CHAIN CERAMIDE-BASED LIPIDS AND USES THEREOF

Provided herein, in some aspects, are delivery vehicles comprising a glycosphingolipid and an agent to be delivered attached to the glycosphingolipid. In some embodiments, the glycosphingolipid comprises an oligosaccharide and a short chain (e.g., C0-C3) ceramide. In some embodiments, the agent to be delivered is a therapeutic agent. The glycosphingolipid is able to deliver the agent to a cell or to a cellular compartment, as well as across the musical barrier. In some embodiments, agents delivered using the glycosphingolipid described herein exhibit longer half-life, compared to agents delivered alone. Methods of delivering a therapeutic agent to a subject for treating a disease using the glycosphingolipid delivery vehicle are also provided.

FERMENTATION

The present invention is directed to a method for decreasing the lag time in a fermentation of a culture medium to prepare a target substance, wherein the target substance is not yogurt and wherein the fermentation results in formation of acid or ethanol, which method comprises the steps of providing, to a suitable culture medium, a fermentation starter culture comprising a microorganism which liberates acid or ethanol, adding a potato protein protease inhibitor to the culture medium, culturing the microorganism, and obtaining the target substance. 1. A method for decreasing the lag time in a fermentation of a culture medium to prepare a target substance , wherein the target substance is not yogurt and wherein the fermentation results in formation of acid or ethanol , which method comprises the steps of providing , to a suitable culture medium , a fermentation starter culture comprising a microorganism which liberates acid or ethanol , adding a potato protein protease inhibitor to the culture medium , culturing the microorganism , and obtaining the target substance.2. A method according to claim 1 , wherein the fermentation results in formation of ethanol.3Saccharomyces, Candida, Zygosaccharomyces, DekkeraBrettanomyces.. A method according to claim 2 , wherein the fermentation starter culture comprises a microorganism from the genus of or4. A method according to claim 2 , wherein the culture medium is a liquid medium comprising plant material.5. A method according to any of claim 2 , wherein the target substance is selected from the group consisting of beer claim 2 , wine claim 2 , champagne claim 2 , sparkling wine claim 2 , cider claim 2 , mead claim 2 , whisky claim 2 , sake or bioethanol.6. A method according to claim 1 , wherein the fermentation results in formation of acid.7Acetobacter, Lactococcus, Lactobacillus, Micrococcus, Streptococcus, Staphylococcus, Kocuria, Leuconostoc, Pediococcus, Debaryomyces, PenicilliumLeuconostoc.. A method according to claim 6 ...

Packaging wine in aluminium containers

A method of filling an aluminum container with wine, and an aluminum container filled with wine, characterized in that the wine has a pH between 2.9 and 3.5 and the filled aluminum container of wine has a molecular sulphur dioxide content of between 0.4 and 0.8 mg/L and further characterized in that prior to filling the wine was micro-filtered in a two stage microfiltration treatment wherein the filter pore diameters are 1.0 μm or less in the first stage filter housing and 0.20 μm to 0.45 μm in at least one subsequent stage filter housing.

RAZOR WIRE CONTAINER WITH ACCESS OPENING

A razor wire barrier or container is disclosed. In some embodiments, the razor wire container includes a plurality of walls defining an interior area for securing object(s) therein. The razor wire container may further include panels or razor wire along a frame defined by the plurality of walls, and a component receptacle extending along the frame. The razor wire container may include a movable access component to provide access to the object(s). The component receptacle is operable to receive a component of a machine for moving the frame. In some embodiments, the component receptacle is a hollow member operable to receive a forklift prong. In some embodiments, the section of razor wire includes one or more panels of razor wire. 1. A razor wire barrier comprising:a frame including a plurality of walls defining an interior area, the plurality of walls each including a section of razor wire;a movable access component to provide access through the plurality of walls; anda component receptacle extending along the frame, the component receptacle operable to receive a component for moving the frame.2. The razor wire barrier according to claim 1 , wherein each of the plurality of walls comprises one or more panels of razor wire.3. The razor wire barrier according to claim 1 , wherein the movable access component is an access panel pivotably coupled to the frame.4. The razor wire barrier according to claim 1 , wherein the movable access component is one of the plurality of walls.5. The razor wire barrier according to claim 1 , wherein the movable access component operably slides vertically along the frame.6. The razor wire barrier according to claim 1 , the frame including a plurality of perimeter posts extending from a floor of the frame.7. The razor wire barrier according to claim 6 , the frame further including a cross post extending between two or more perimeter posts of the plurality of perimeter posts.8. The razor wire barrier according to claim 7 , wherein each of ...

SYSTEM FOR THE PROPAGATION OF YEAST AND ADAPTATION FOR SECONDARY FERMENTATION IN THE PRODUCTION OF SPARKLING WINES

The invention relates to a system for the propagation of yeast and adaptation to ethanol in a sustained manner using a bioreactor () which is programmed automatically and in which the propagation and adaptation to ethanol, pH and temperature is carried out, for a secondary fermentation in the tirage of Cava, Champagne and sparkling wines in general. The bioreactor () includes a motor () with stirring blades, and a temperature-control system comprising a sleeve and an electrical resistor, said bioreactor () being associated with a mixing tank () which houses the liquor. In addition, a programmed pump () is provided between the bioreactor () and the mixing tank (), as well as a programmable automaton with a control panel () for automating the process. 112421254. A system for yeast propagation and adaptation for second fermentation in the generation of sparkling wines , characterised as comprising a bioreactor () for yeast propagation and a mixing tank () containing a liquor , and including a programmed pump () for delivering said liquor from the tank () to the bioreactor () from the mixing tank () , as well as a programmable automaton with a control panel () for process automation connected and driving said programmed pump ().216131320111. The system set forth in claim 1 , wherein the bioreactor () includes a motor with mixing blades () claim 1 , as well as air diffusors () having corresponding filters (′) claim 1 , and including a cooling chamber () coupled to internal resistances () for temperature control inside said bioreactor (); further including a flow sensor to regulate the entry of filtered air as required by the yeasts to propagate.31243. The system set forth in claim 2 , wherein the bioreactor () claim 2 , mixing tank () and programmed pump () are mounted on a common frame ().4218. The system set forth in claim 3 , wherein mixing tank () includes a stirring motor ().5127171419. The system set forth in claim 4 , wherein the bioreactor () and the mixing tank ...

Process for preparing sparkling wine cocktails

The present invention refers to the food industry. More specifically, the present invention refers to a method for preparation of cocktails which are based on sparkling wine, such as Cava, whereby it is possible to obtain cocktails at industrial scale with an appearance of coloured pearl, and when putting the bottle in motion simulates ocean waves, which is extremely attractive for consumption, especially in night clubs and discotheques. In addition, with the method of the present invention properties of the based sparkling wine are kept in the prepared cocktail.

PROCESS FOR PREPARING SPARKLING WINE COCKTAILS CONTAINING EDIBLE GOLD

The present invention refers to the food industry. More specifically, the present invention refers to a method for preparation of cocktails which are based on sparkling wine, such as Cava, whereby it is possible to obtain at industrial cocktails containing edible gold in suspension, with a visual appearance of multiple flashes, and when putting the bottle in motion it makes that the prepared cocktail acquires a particular dynamism, which is extremely attractive for consumption, specially in night clubs and discotheques. In addition, with the method of the present invention properties of the based sparkling wine in the prepared cocktail are kept. 1. Method for producing sparkling wine cocktails containing edible gold , characterized in that it comprises the steps of:a) taking a volume between 700 and 800 ml of based sparkling wine;b) adjusting temperature of said based sparkling wine between 2° C. and 20° C.;c) preparing a mixture comprising edible gold (code E-175) in an amount of said edible gold between 0.5 mg and 500 mg, sweetener, flavour, preservatives and, optionally, other food colorants;f) adding the mixture prepared is step c) to the based sparkling wine; andg) filling, closing, capsulation and labelling of bottles.2. Method claim 1 , according to claim 1 , characterized in that the based sparkling wine is a gasified wine of endogenous origin.3. Method claim 2 , according to claim 2 , characterized in that the based sparkling wine is a Cava.4. Method claim 1 , according to claim 1 , characterized in that the based sparkling wine is a wine with exogenous gasification.5. Method claim 4 , according to claim 4 , characterized in that the method comprises a further step of injection of carbon dioxide. The present invention refers to the food industry. More specifically, the present invention refers to a method for preparation of cocktails which are based on sparkling wine, such as Cava, whereby it is possible to obtain at industrial cocktails containing edible ...

DEVICE FOR THE CONTROLLED TRANSFER OF VOLATILE GASES OR GASEOUS MOLECULES INTO A CONTAINER INTENDED TO CONTAIN A LIQUID OR SEMI-LIQUID FOOD PRODUCT

According to the invention, this device includes a rigid capsule () forming a chamber () whereof one longitudinal end () is open, and forming a longitudinal duct () for the flow of a liquid or semi-liquid food product (); an active product () contained in the chamber (), capable of absorbing a gas and/or volatile gaseous molecules present in the food product (), or of diffusing a volatile gas and/or gaseous molecules into the food product (); a cap () for closing the open longitudinal end () of the chamber (, having a penetrable septum (), the cap () being able, when it is placed on the capsule () and its septum () is not perforated, to close the chamber () so that it is sealed against gases and water, and allowing, when it is perforated, a transfer of volatile gases and/or gaseous molecules between the outside and the inside of the chamber (), and a membrane () permeable to the volatile gases and/or gaseous molecules to be absorbed or diffused, placed in the chamber () so as to separate the active product () contained in the chamber () from the outside. The invention also relates to a closure for a container as described above, comprising the device (), a method for manufacturing a container comprising such a closure, and a machine for implementing this method. 1. A controlled gas transfer device for the controlled transfer of volatile gases or gaseous molecules into a container intended to contain a liquid or semi-liquid food product , the device comprising:{'b': '6', 'i': 'a', 'a rigid capsule forming a chamber whereof one longitudinal end () is open, and forming a longitudinal duct for the flow of a liquid or semi-liquid food product;'}an active product contained in the said chamber, capable of absorbing a volatile gas and/or volatile gaseous molecules present in the said food product or of diffusing a volatile gas and/or volatile gaseous molecules in this food product;a closure cap for closing the said open longitudinal end of the chamber, comprising a ...

Polymer nanoparticle composition for plasmid dna delivery, and preparation method therefor

Disclosed are a pharmaceutical composition containing plasmid DNA, characterized by that it comprises plasmid DNA as active ingredients; a peptide comprising a nuclear localization signal (NLS) sequence or RGD peptide sequence; a cationic compound; and an amphiphilic copolymer, and the plasmid DNA binds to a peptide to form a complex with the cationic compound and the complex is entrapped in the nanoparticle structure of the amphiphilic block copolymer, and a preparation method thereof.

Method and composition for a protein transduction technology and its applications

A protein transduction method for efficiently delivery of exogenous proteins into mammalian cells is invented, which has the capability of targeting different cellular compartments and protection from degradation of the delivered proteins from cellular proteases. A composition for treat proteins has cation reagents, lipids and enhancers in a carrier. The method can be used in a number of ways including: production of large quantities of properly folded, post-translationally modified proteins using mammalian cell machinery a in-cell fluorescence spectroscopy and imaging using small molecule fluorophores and a in-cell NMR spectroscopy using living mammalian cells. The method permits cell biology at atomic resolution that is physiologically and pathological relevant and permits protein therapy to treat human diseases. The method can also be used to deliver exogenous protein inside mammalian cells, wherein the exogenous proteins follow a similar secretion pathway as that of the endogenous protein.

HYBRID CARRIERS FOR NUCLEIC ACID CARGO

The invention relates to carrier compositions for nucleic acid delivery which comprise a cationic peptide or polymer in combination with a cationic lipid. In a further aspect, the invention relates to nanoparticles comprising a complex of a bioactive cargo material with the peptide or polymer and the lipid. The invention further relates to the preparation and the uses of the nanoparticles. 2. The composition of claim 1 , wherein the weight ratio of the cationic peptide or polymer to the nucleic acid compound is at least about 1 claim 1 , and wherein the ratio of the cationic lipid to the nucleic acid compound is not higher than about 15 nmol/μg.3. The composition of claim 1 , wherein the weight ratio of the cationic lipid to the cationic peptide or polymer is not higher than about 1:50 claim 1 , and/or wherein the ratio of the cationic lipid to the cationic peptide or polymer is not higher than about 2 nmol/m.4. The composition of claim 1 , having an N/P ratio from about 0.1 to about 20 claim 1 , or from about 0.2 to about 15 claim 1 , or from about 2 to about 15 claim 1 , or from about 2 to about 12 claim 1 , wherein the N/P ratio is defined as the mole ratio of the nitrogen atoms of the basic groups of the cationic peptide or polymer to the phosphate groups of the nucleic acid compound.6. The composition of claim 1 , wherein the cationic lipid is a PEGylated lipid.7. (canceled)8. The composition of claim 5 , whereinX is selected from a tertiary amino group, in particular dimethylaminoalkyl, such as dimethylaminoethyl, dimethylaminopropyl, or dimethylaminobutyl; or from a quaternary ammonium group, in particular a trimethylammonium group, and/or{'sup': 1', '2, 'Y, Yand/or Yare selected from linking groups comprising an ester or amide bond or a dioxolane ring; and/or'}Z is a steroid residue; and/or{'sup': 1', '2', '3, 'Z, Z, and/or Zare selected from saturated or unsaturated hydrocarbon chains with 14 to 22 carbon atoms.'}9. The composition of claim 5 , wherein the ...

APPARATUS FOR PROCESSING ORGANIC PRODUCTS AND OTHER MATERIALS

Method for processing organic material is disclosed which breaks down the inedible components of fruit and vegetables (core, skin, pips, pithy material) into an edible substance with a cream-like consistency. The method includes pressurizing the material and forcing it through a passage having a number of end-to-end sections which are at right angles to one another. The material as it emerges from each section impacts on the impact surface at the end of each section and changes direction and flows into the next section of the series. 1. A method of processing organic material which comprises forcing the material under a pressure of between 200 and 2000 bar into a bore so that it emerges from the bore at a speed of between 500 and 6000 kph , causing the material to flow from the bore through a passage comprising a plurality of sections each of which has an inlet end and an outlet end and each of which is at an angle with respect to the section which precedes it so that the material changes direction as it flows from one section to the next , and providing an impact wall at the outlet end of each section so that the material , as it emerges from each section , impacts on the impact wall at the end of that section , changes direction and flows into the next section of the plurality of sections.2. The method according to claim 1 , wherein the pressure is between 300 and 1600 bar.3. The method according to claim 2 , wherein the pressure is between 350 and 1200 bar.4. The method according to claim 1 , wherein the speed is between 2000 and 4000 kph.5. A method of processing organic material which comprises forcing the material at a pressure of 200 bar or above through a bore having a diameter of between 0.05 mm and 8 mm claim 1 , causing the material to flow from the bore through a passage comprising a plurality of sections each of which has an inlet and an outlet and which is at an angle with respect to the section which precedes it so that the material changes direction ...

GAS-INFUSED FLUIDS AND METHODS OF MAKING AND USING SAME

The present disclosure provides fluids, such as a distilled spirit, comprising at least about 25 ppm of an infused gas. Systems and methods for producing such gas-infused fluids are also provided. 1. A system for producing a gas infused fluid , the system comprising:(a) a compressed oxygen source;(b) a gas infusion chamber for receiving the fluid, wherein the gas infusion chamber is in communication with the compressed oxygen cylinder; and(c) a micromembrane in the gas infusion chamber, wherein the micromembrane has a pore channel diameter of about 0.05 μm to about 5.0 μm.2. The system of claim 1 , wherein the fluid is a beverage.3. The system of claim 2 , wherein the beverage comprises ethanol.4. The system of claim 3 , wherein the beverage is a distilled spirit.5. The system of claim 4 , wherein the distilled spirit is selected from the group consisting of: gin claim 4 , rum claim 4 , bourbon claim 4 , cognac claim 4 , tequila claim 4 , whiskey claim 4 , brandy claim 4 , grappa claim 4 , vodka claim 4 , and a liqueur.6. The system of claim 3 , wherein the beverage is beer.7. The system of claim 3 , wherein the beverage is wine.8. The system of claim 2 , wherein the beverage is a nutritional beverage.9. The system of claim 1 , wherein the fluid is a therapeutic fluid.10. The system of claim 2 , wherein the fluid comprises at least about 15 ppm of oxygen.11. The system of claim 10 , wherein the fluid comprises at least about 25 ppm of oxygen.12. The system of claim 10 , wherein the fluid comprises at least about 30 ppm of oxygen.13. The system of claim 10 , wherein the fluid comprises at least about 50 ppm of oxygen.14. The system of claim 10 , wherein the fluid comprises at least about 75 ppm of oxygen.15. The system of claim 10 , wherein the fluid comprises at least about 100 ppm of oxygen.16. The system of claim 10 , wherein the fluid comprises at least about 150 ppm of oxygen.17. The system of claim 10 , wherein the fluid comprises at least about 200 ppm of ...

MYCOTOXIN-BINDERS

The present technology relates to novel mycotoxin binder and the use in animal feed. The present disclosure relates also to the use of enzymes for improving the mycotoxin binding ability of by-products derived from a fermentative production process and to compositions comprising enzymes capable of degrading components in the fermented mash in the fermentation process. 131-. (canceled)32. A method for improving the mycotoxin binding ability of a by-product derived from a fermentative production process comprising the steps of:i) subjecting fermented mash after fermentation to an enzyme composition capable of degrading one or more fermented mash components;ii) separating a desired primary fermentation product; andiii) separating the fermentation by-product having mycotoxin binding abilities.33. The method according to claim 32 , wherein the enzyme composition comprises a beta-1 claim 32 ,3-glucanase.34. The method according to claim 32 , wherein the fermented mash is derived from a fermentative alcohol production process and the desired primary fermentation product is an alcohol.35. The method according to claim 32 , wherein the fermented mash is derived from starch-containing material including starch-containing material selected from the group consisting of corn claim 32 , wheat claim 32 , barley claim 32 , triticale claim 32 , cassava claim 32 , sorghum claim 32 , rye claim 32 , potato claim 32 , or any combination thereof.36. The method according to claim 35 , wherein the desired primary fermentation product is separated by distillation.37. The method according to claim 32 , wherein the by-product is selected from the group consisting of distillers' wet grain (DWG) claim 32 , distillers' dried grains (DDG) claim 32 , distillers' solubles (DS) claim 32 , distillers' dried solubles (DDS) claim 32 , distillers' dried grain with solubles (DDGS) claim 32 , and mixtures thereof.38. A method for producing a mycotoxin free by-product derived from a fermentative production ...

ENZYMATIC METHOD FOR REMOVING SULPHITE

The present invention relates to an enzymatic method for removing sulphite. In particular, the present invention relates to a method for converting sulphite present in a composition into thiosulphate, comprising the introduction of 3-mercaptopyruvate sulphurtransferase (3-MST) and a substrate of said 3-mercaptopyruvate sulphurtransferase into said composition. The present invention can be used in particular in the pharmaceutical, cosmetic, food and chemical fields, and any field involving the use of sulphite. 1. A method for treating a composition , comprising introducing into said composition 3-mercaptopyruvate sulfurtransferase (3-MST) and a substrate of said 3-mercaptopyruvate sulfurtransferase in order to convert sulfites in the composition.2. A method for converting sulfite present in a composition into thiosulfate , comprising introducing into said composition 3-mercaptopyruvate sulfurtransferase (3-MST) and of a substrate of said 3-mercaptopyruvate sulfurtransferase and converting the sulfite present in the composition into thiosulfate.3. The method as claimed in claim 1 , wherein said 3-mercaptopyruvate sulfurtransferase is recombinant.5Escherichia coli.. The method as claimed in claim 1 , wherein said 3-mercaptopyruvate sulfurtransferase is from6. The method as claimed in claim 1 , wherein the 3-mercaptopyruvate sulfurtransferase is a protein or peptide sequence selected from the group SEQ ID Nos 2 claim 1 , 5 claim 1 , 6 and 7.7. The method as claimed in claim 1 , wherein the composition is an agri-food claim 1 , pharmaceutical claim 1 , cosmetic or veterinary composition.8. The method as claimed in claim 1 , wherein said substrate of said 3-mercaptopyruvate sulfurtransferase is 3 mercaptopyruvate.9. The method as claimed in claim 1 , wherein the stoichiometric ratio of said substrate to the sulfite present in said composition is at most 1:1.10. The method as claimed in claim 1 , wherein said 3-mercaptopyruvate sulfurtransferase is recombinant. ...

APTAMER-DRUG CONJUGATE AND USE THEREOF

A cancer targeted therapeutic agent includes a drug-linker-AS1411 structure. The drug may be selected from monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), cytarabine, gemcitabine, maytansine, DM1, DM4, calicheamicin and a derivative thereof, doxorubicin, duocarmycin and a derivative thereof, pyrrolobenzodiazepine (PBD), SN-38, a-amanitin, or a tubulysin analog. 14-. (canceled)6. The cancer targeted therapeutic agent of claim 5 , wherein the drug is monomethyl auristatin E (MMAE) or cytarabine.7. The cancer targeted therapeutic agent of claim 5 , wherein Y is maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl (MC-Val-Cit-PAB) or maleimidocaproyl-glycine-phenylalanine-leucine-glycine (MC-Gly-Phe-Leu-Gly) claim 5 , X is 5′-thiol-modifier C6 claim 5 , and Y has a side of maleimidocaproyl bound to the drug and the other side bound to X.8. The cancer targeted therapeutic agent of claim 5 , wherein the modified AS1411 has the sequence of SEQ ID NO: 9. This application claims benefit under 35 U.S.C. 119(e), 120, 121, or 365(c), and is a National Stage entry from International Application No. PCT/KR2017/014060 filed on Dec. 4, 2017, which claims priority to the benefit of Korean Patent Application No. 10-2016-0179111 filed in the Korean Intellectual Property Office on Dec. 26, 2016, the entire contents of which are incorporated herein by reference.The present invention relates to an [anti-nucleolin GRO aptamer]-Toxin conjugate for treatment of targeted cancer and a synthetic method thereof, and more particularly, to an [anti-nucleolin aptamer]-Toxin conjugate with verified in vitro/vivo efficacy, thereby exhibiting excellent effects in treatment of cancer, as well as use thereof.Until now, numerous therapeutic agents including anticancer drugs have been developed and proposed as medicines through clinical trials. However, how to choose and effectively deliver some materials having desired therapeutic effects such as targeted anticancer drugs to the ...

BORONIC ESTER PRODRUGS AND USES THEREOF

Disclosed herein are compounds of Formula (I) or (II). The compounds include an agent (e.g., pharmaceutical agent, cosmetic agent, or nutraceutical agent) through a linker that includes a boronic ester moiety in the backbone of the linker. The compounds may be monomers. Also provided are polymers prepared by polymerizing the monomers. The polymers may be useful for delivering the agent to a subject, tissue, biological sample, or a cell. Also provided are methods of preparing the polymers, compositions and kits comprising the polymers, and methods of use (e.g., use in delivering the agent, treating a disease, preventing a disease, diagnosing a disease) involving the polymers or compositions. The structure of the boronic ester moiety may be fine tuned so that the properties related to delivery to a subject, biological sample, tissue, or cell may be fine tuned. 3. (canceled)4. The compound of claim 1 , or a salt thereof claim 1 ,{'sub': '3', 'wherein X is —N.'}522-. (canceled)2450-. (canceled)5268-. (canceled)69. The compound of claim 1 , or a salt thereof claim 1 , wherein at least one instance of the agent is bortezomib.7073-. (canceled)77. A method of preparing a polymer comprising polymerizing a compound claim 1 , or a salt thereof claim 1 , wherein X is a polymerization handle.7882-. (canceled)83. A method of preparing a polymer comprising reacting an existing polymer with a compound of claim 1 , or salt thereof claim 1 , wherein the existing polymer comprises a reaction handle able to react with X claim 1 , and in the step of reacting claim 1 , the reaction handle able to react with X is reacted with X.8485-. (canceled)86. A polymer prepared by a method of .87. A composition comprising:{'claim-ref': {'@idref': 'CLM-00002', 'claim 2'}, 'a polymer of ; and'}optionally an excipient.8889-. (canceled)90. A kit comprising:{'claim-ref': {'@idref': 'CLM-00002', 'claim 2'}, 'a polymer of ; and'}instructions for using the polymer.91. A method of delivering an agent to a ...

Aromatized Effervescent Wine

The invention relates to an effervescent wine obtained according to a vinification of the traditional type, comprising a mixture of at least 20 terpenes added to said wine, wherein the terpenes are chosen from monoterpenes, in a quantity within the range of 50% by weight to 75% by weight, sesquiterpenes, in a quantity within the range of 25% by weight to 50% by weight, the sum being equal to 100% by weight, the quantity in said mixture of terpenes in the wine being between 0.02 ml and 0.6 ml per litre of effervescent wine. The invention also relates to a traditional method of vinification of an effervescent wine comprising a step of adding an expedition liqueur comprising the mixture of terpenes. 1. Effervescent wine obtained according to a vinification of the traditional type , comprising a mixture of at least 20 terpenes added to said wine , wherein the terpenes are chosen from monoterpenes , in a quantity within the range of 50% by weight to 75% by weight , sesquiterpenes , in a quantity within the range of 25% by weight to 50% by weight , the sum being equal to 100% by weight , the quantity in said mixture of terpenes in the wine being between 0.02 ml and 0.6 ml per litre of effervescent wine.2. Effervescent wine according to claim 1 , wherein the terpenes in the mixture comprise monoterpenes chosen from the sub-families of acyclic monoterpenes claim 1 , of monocyclic monoterpenes claim 1 , of bicyclic monoterpenes claim 1 , of acyclic monoterpene alcohols claim 1 , of monocyclic monoterpene alcohols claim 1 , of bicyclic monoterpene alcohols claim 1 , of ether-cyclic monoterpenes and of monoterpene ketones claim 1 , the sub-families of sesquiterpenes being chosen from monocyclic sesquiterpenes claim 1 , bicyclic sesquiterpenes claim 1 , acyclic sesquiterpene alcohols and monocyclic sesquiterpene alcohols claim 1 , or the mixtures thereof.3. Effervescent wine according to claim 1 , wherein the monoterpenes further comprise monoterpene oxides claim 1 , and the ...

FOLDABLE MODULAR PACKAGING, IN PARTICULAR FOR INDUSTRIAL PRODUCTS

The present invention concerns a foldable modular packaging (), characterised in that it comprises: at least four panels () that can be moved between a folded position, in which the panels () are stacked on each other, and an unfolded position, in which the panels () form a parallelepiped frame () defining an internal volume (); a flexible inner container () suitable for being arranged in said internal volume (); and an assembly system () comprising linking elements () forming a pivot link between each panel () and at least one adjacent panel (). 111. Foldable modular packaging () , wherein the packaging () comprises:{'b': '10', 'claim-text': [{'b': '10', 'a folded position, in which the panels () are stacked on each other, and'}, {'b': 10', '11', '12, 'an unfolded position, in which the panels () form a parallelepiped frame () which, defining an internal volume ();'}], 'at least four panels () which can move between{'b': 20', '12, 'a flexible inner container () able to be placed in the said internal volume (); and'}{'b': 30', '31', '10', '10, 'an assembly system () comprising linking elements () forming a pivot link between each panel () and at least one adjacent panel ().'}212010. Packaging () according to claim 1 , wherein in the folded position claim 1 , the flexible inner container () is retracted between the panels ().3110. Packaging () according to claim 1 , wherein the panels () are interchangeable.4110. Packaging () according to claim 1 , wherein the panels () are flat.51311010. Packaging () according to claim 1 , wherein the linking elements () form a 360 degree pivot link between each panel () and at least one adjacent panel ().6111011. Packaging () according to claim 1 , wherein the packaging () comprises six movable panels () able to form the parallelepiped frame ().71140101504041425150. Packaging () according to claim 1 , wherein the packaging () comprises a lower frame () designed to be interposed between a lower panel () of the packaging () and a ...

PROCESS FOR OBTAINING A SPARKLING ALCOHOLIC BEVERAGE WHERE WINE MACERATED IN HOPS IS MIXED WITH VEGETABLE WATER AND/OR WATER, AND ADDITION OF WINE CONCENTRATE AND CONCENTRATED FRUIT AND/OR VEGETABLE JUICE

The present invention discloses a process for preparing a sparkling alcoholic beverage resulting from the maceration of hops and/or its derivatives in wine with the addition of wine concentrate, vegetable water and/or water, fruit or vegetable concentrate and/or sugar, in order to reduce the alcohol content of wine, and which is gasified by a second alcoholic fermentation and/or addition of carbon dioxide. Through this process a sparkling alcoholic beverage having between 5 and 15% alcohol, a sugar content between 0.1 and 200 g/L, with a total acidity between 4 and 8 g/L is obtained having hops aroma, flavor and bitterness combined with aromas inherent to wine. 1. A process for obtaining a sparkling alcoholic beverage , comprising the following steps:a. receiving white, pink or black grapes clusters, separating grains from stems of the grape clusters, and crushing the grains;b. adding between 0.1 and 10 g/hL of pectolytic enzyme and/or cellulases and/or hemicellulases to the crushed grains of step (a) and pressing said mixture of crushed grains and enzymes in a pneumatic press separating grape juice from skins and seeds;c. clarifying the grape juice obtained in step (b), separating by decantation solids from grape juice by adding between 0.1 and 10 g/hL of pectolytic enzymes, cellulases and hemicellulases;{'i': 'Saccharomyces cerevisiae', 'd. fermenting the clarified grape juice of step (c) by adding yeasts selected from genus at doses between 10 and 50 g/hL and nitrogen compounds at doses between 10 and 100 g/hL;'}e. clarifying the wine obtained in step (d) by physically separating the solid residues generated in the fermentation step by using drawing-off and/or centrifugation and/or earth, tangential or cloths filters; obtaining a wine with a turbidity level between 20 and 100 NTU;f. stabilizing the wine from precipitation of tartaric salts;g. adding hops or derivatives thereof to the wine obtained in step (f) at a dose between 0.1 and 10 g/L and macerating at ...

Membrane-penetrating peptides to enhanced transfection and compositions and methods for using same

The present invention is directed to non-naturally occurring peptides containing a membrane-penetrating amino acid sequence and further at least one polycationic moiety or peptide sequence. The peptides are suitable for use in delivery a cargo to the interior of a cell. Suitable cargo includes nucleic acid molecules (including DNA, RNA or PNA), polypeptides, or other biologically active molecules. The present invention is further directed to transfection complexes containing the non-naturally occurring peptides of the present invention in non-covalent association with at least one cationic lipid and a cargo to be delivered to the interior of a cell. The invention further relates to methods for the preparation and use of the non-naturally occurring peptides for the formation of transfection complexes and the delivery of a cargo to the interior of a cell in culture, an animal or a human. The invention also relates to compositions and kits useful for transfecting cells.

MODULAR PALLET SYSTEM FOR TRANSPORTING BULKY AND FRAGILE GOODS IN A MULTI-STORY CONSTELLATION

Modular pallet system for transporting bulky and fragile goods in a multi-story constellation, the system consists of the modules basic-pallet, vertical-pillars, longitudinal-reinforce-elements and transversal-reinforce-elements. The basic-pallet provides the surface for placing the cargo and for lashing via integrated tie-down points. Further junction points at the edges of the basic-pallet are for the connection with the vertical-pillars and through these with the reinforce elements, necessary to provide the assembly's stability, enabling stack ability with additional basic-pallets on top. 1. A modular pallet transport system , to be assembled in a toolbox principle , comprising modules of basic-pallet , vertical-pillars , longitudinal-reinforce-elements and transversal-reinforce-elements , for the transport of big and bulky goods and capable to be stapled also with heavy payload in a transport vehicle.2. A pallet system according to claim 1 , as the basic pallet (P) comprising modules of two vertical pillar (VP) and two transversal reinforce (RT) claim 1 , connected together perpendicularly.3. The basic pallet (P) according to claim 2 , the connection of modules takes place via standard-screws (M16) or alternative via plug-connection.4. The basic pallet (P) according to claim 2 , is made of a solid steel frame with two wooden top surfaces.5. The basic pallet (P) according to claim 2 , characterized in a staple dimension is in range of (80-220) mm/pallet.6. A pallet system according to claim 1 , as the modules vertical-pillar (VP) & the reinforce-longitudinal (RL) are the sides of the toolbox.7. The modules according to claim 6 , are connected together via standard-screws (M8 up to M36).8. The modules according to claim 6 , are made of steel elements.9. The modules according to claim 1 , the length of the vertical pillar is (500-1800) mm long.10. The modules according to claim 6 , the weight of (VP) is in a range of (0.8-25.0) kg/ea & of (RL) is in a range of (0.8 ...

RNA INTERFERENCE MEDIATED TARGET DISCOVERY AND TARGET VALIDATION USING SHORT INTERFERING NUCLEIC ACID (siNA)

The present invention concerns methods and reagents useful in target discovery. Specifically, the invention relates to small nucleic acid molecules capable of mediating RNA interference (RNAi), such as short interfering nucleic acid (siNA) short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods of target discovery using siRNA.

Vitamin-targeted imaging agents

The invention relates to compounds and methods for targeting radionuclide-based imaging agents to cells having receptors for a vitamin, or vitamin receptor binding derivative or analog thereof, by using such a vitamin as the targeting ligand for the imaging agent. The invention provides a compound of the formula for use in such methods. In the compound, V is a vitamin that is a substrate for receptor-mediated transmembrane transport in vivo, or a vitamin receptor binding derivative or analog thereof, L is a divalent linker, R is a side chain of an amino acid of the formula H 2 NCHRCOOH, M is a cation of a radionuclide, n is 1 or 0, K is 1 or 0, and the compound can be in a pharmaceutically acceptable carrier therefor. The vitamin-based compounds can be used to target radionuclides to cells, such as a variety of tumor cell types, for use in diagnostic imaging of the targeted cells.

医薬品製剤

　本発明の医薬品製剤は、標的部位を特異的に認識する配位子（リガンド）構造、鎖状親水性基、疎水性もしくは両親媒性の基を有する両親媒性化合物を含有する医薬品製剤である。本発明の医薬品製剤は、適度の柔軟性を有する鎖状親水性基を導入した特定の構造の両親媒性化合物を用いており、薬物標的指向化（ターゲッティング）に好適な微粒子となる。 本発明の医薬品製剤は、薬理効果の持続が期待できる。顕著な部位指向性の示される粒子製剤を形成できる。また、本発明の医薬品製剤は、マトリックス形成材料の選択により、薬物の放出特性の制御も可能となる。

COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF

Disclosed herein are novel compounds for degrading Tau protein aggregates, pharmaceutical acceptable salts, enantiomers, non-enantiomers, tautomers, racemates, solvates, metabolic precursors, or prodrugs thereof. Also disclosed herein are uses of the compounds, pharmaceutical acceptable salts, enantiomers, non-enantiomers, tautomers, racemates, solvates, metabolic precursors, or prodrugs thereof in the manufacture of a medicament for treating a tauopathy, as well as method for aiding in the treatment of a tauopathy or treating a tauopathy in a subject. 2. The compound of claim 1 , or the pharmaceutical acceptable salt claim 1 , the enantiomer claim 1 , the tautomer claim 1 , the racemate claim 1 , or the solvate thereof claim 1 , wherein the substituted or unsubstituted bicyclic fused aromatic ring is a substituted or unsubstituted bicyclic 5-6 system.6. The compound of claim 5 , or the pharmaceutical acceptable salt claim 5 , the enantiomer claim 5 , the tautomer claim 5 , the racemate claim 5 , or the solvate thereof claim 5 , wherein Lis an optionally substituted Chydrocarbon chain claim 5 , optionally wherein one or more chain atoms of the hydrocarbon chain are independently replaced with —C(═)— claim 5 , —O— claim 5 , —NR— claim 5 , —S— or a cyclic moiety claim 5 , wherein Ris independently hydrogen claim 5 , substituted or unsubstituted Calkyl or a nitrogen protecting group.7. The compound of claim 5 , or the pharmaceutical acceptable salt claim 5 , the enantiomer claim 5 , the tautomer claim 5 , the racemate claim 5 , or the solvate thereof claim 5 , wherein Lis selected from the group consisting of substituted or unsubstituted carbocyclylene claim 5 , substituted or unsubstituted heterocyclylene claim 5 , substituted or unsubstituted arylene claim 5 , substituted or unsubstituted heteroarylene claim 5 , or substituted or unsubstituted heteroalkylene claim 5 , and combinations thereof.8. The compound of claim 7 , or the pharmaceutical acceptable salt claim 7 ...